Document:

EXHIBIT
10.1

    

     DETERMINATION
PURSUANT TO COMPENSATION AND SERVICES AGREEMENT

    

    On June
14, 2010, the Board of Directors
approved and we and Majestic Property Management Corp. agreed that
effective as of January 1, 2010, the annual fee payable to Majestic pursuant to
the Compensation and Services Agreement (the “Agreement”) would be
increased by $200,000 to $2,225,000, which
determination was made in accordance with the terms of the
Agreement.Exhibit
10.5

    

    Description of Director
Compensation Arrangements for the 12 month period ending at 

    the 2011 Annual Meeting of
Shareholders

    

    German
American Bancorp, Inc. (the "Company"), compensates its directors for their
service to the Company and the Company's subsidiaries based on a twelve-month
period commencing with each year's annual reorganization meeting of the
Board.  The Governance/Nominating Committee made a recommendation with
respect to director compensation to the Board and the Board approved such
recommendation at its annual reorganization meeting on June 28,
2010.

    

    For
services of directors during the current annual period that commenced at the
2010 annual meeting, the Company is compensating its directors, including the
CEO, through an annual retainer of $20,000 paid in cash during July 2010 in a
lump sum (which is earned regardless of the number of meetings held or attended,
and regardless of committee membership or attendance) and is paying an
additional attendance fee of $500 for each meeting of the Board that they attend
during this period.

    

    In
addition, directors of the Company receive a meeting fee for each committee
meeting that they attend of $350.

    

    Additional
annual retainers (earned regardless of numbers of meetings held or attended) are
paid for service as the Board’s lead director ($3,500) and for service as the
Chairman of each of three committees of the Board:  Audit Committee,
Compensation/Human Resources Committee, and Credit Risk Management Committee
($3,500 to each such Chairman).

    

    In
addition, those members of the Board (other than the CEO, who as a salaried
employee of the Company is ineligible) who serve on the board of directors
(including any regional advisory board) of at least one of the subsidiaries
receives additional compensation for his or her service to such subsidiaries in
the form of director/advisory fees for meetings actually attended of (i) $500
per meeting of the board of directors of German American Bancorp (our bank
subsidiary) or of any regional advisory board, (ii) $350 for any meeting of a
committee of the board of directors of our bank subsidiary, and (ii) $350
(combined for attendance at both meetings) per meeting of the boards of
directors of German American Financial Advisors & Trust Company and German
American Insurance, Inc. (which are held quarterly and
sequentially).

    

    Directors
attending concurrent sessions of German American Bancorp, Inc. and German
American Bancorp Board and committees receive a single meeting fee of $500 for
the combination of the two meetings.Unassociated Document

     

    
      
        
          	
                  Agreement
      for the Supply of Services Relating
      to

                  Development
      Materials

                

        

      

    

    
Agreement
for the

    Supply
of Services Relating to Development Materials

    between
Novartis Pharma AG and GenVec, Inc.

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
        1

        
          

        

      

      
         

      

    

     

    
      
        
          
            	
                    Agreement
      for the Supply of Services Relating
      to

                    Development
      Materials

                  

          

        

      

    

    
Agreement
between

    

    Novartis
Pharma AG

    
      Forum
1

    

    
      Novartis
Campus

    

    
      4056
Basel

    

    
      Switzerland

    

    

    hereinafter
together or individually, as the context requires, referred to as
“Novartis”

    

    and

     

    
      GenVec,
Inc.

      65 West
Watkins Mill Road

      Gaithersburg

      Maryland
20878

      United
States

    

    

    hereinafter
referred to as “GenVec”

    

    
      	
              Whereas:

            	
              Novartis
      and GenVec entered into a Research Collaboration and License Agreement
      dated January 13, 2010 (the “Collaboration
  Agreement”);

            

    

    and

    

    
      	
              Whereas:

            	
              Subject
      to the applicable provisions of the Collaboration Agreement, this
      Agreement sets forth the terms and conditions upon which GenVec will
      perform the Services, which Services constitute, in part, GenVec’s
      activities in support of the Collaboration
  Agreement.

            

    

    

    
      NOW THEREFORE, the parties
agree as follows:

    

    

    
      	
              1.

            	
              Scope
      of Agreement

            

    

    

    
      	
              1.1

            	
              This
      Agreement shall form the framework of contractual conditions under which
      GenVec and its Affiliates will provide services relating to Development
      Materials as specified in Work Orders which have been executed by the
      parties and which specifically refer to this Agreement (the
      “Services”).

            

    

    

    
      	
              1.2

            	
              Subject
      to the terms and conditions of this Agreement (including any Work Order),
      Novartis may request the following Services from GenVec and/or any of its
      Affiliates under this Agreement:

            

    

    

    
      
        	
                
                

              	
                (a)

              	
                Development
      of formulation of galenical forms of drug product and
      analytics;

              

      

    

     

    * The asterisk denotes that
confidential portions of this exhibit have been omitted in reliance on Rule
24b-2 of the Securities Exchange Act of 1934. The confidential portions have
been submitted separately to the Securities and Exchange Commission.

     

    
      
        
        

      

      
        2

        
          

        

      

      
        
        

      

    

     

    
      
        
          
            	
                    Agreement
      for the Supply of Services Relating
      to

                    Development
      Materials

                  

          

        

      

    

     

    
      
        	
                
                

              	
                (b)

              	
                Manufacture
      and analysis of Development Materials, including without limitation drug
      products for use in clinical
studies;

              

      

    

    
      
        	
                
                

              	
                (c)

              	
                Manufacture
      and analysis of placebos for use in clinical
  studies;

              

      

    

    
      
        	
                
                

              	
                (d)

              	
                Stability
      testing of drug products, including for registration purposes;
      and/or

              

      

    

    
      
        	
                
                

              	
                (e)

              	
                Any
      other services as may be agreed by the parties in
  writing.

              

      

    

    

    
      	
              1.3

            	
              Upon
      execution of any Work Order by GenVec or any of its Affiliates, and by the
      Novartis entity issuing the Work Order, GenVec (and the respective
      Affiliate of GenVec if applicable) and the relevant Novartis entity shall
      be bound by this Agreement in respect of such Work
  Order.

            

    

    

    
      	
              1.4

            	
              Within
      fifteen days upon execution of the Agreement Genvec shall
      supply  * to Novartis * and in accordance with Section 5 in
      Annex B and shall  grant to Novartis and its Affiliates (i) an
      non-exclusive, royalty-free, perpetual, sublicenseable license to use
      the  * to (further) develop, use, make, have made, market, offer
      to sell, sell, have sold, distribute, import, export and otherwise
      commercialize the Development Materials and/or Products in the Field (as
      defined in the Collaboration Agreement) in the Territory (as defined in
      the Collaboration Agreement),

            

    

    

    
      	
              2.

            	
              Elements
      of the Agreement

            

    

    

    The
following documents and annexes form an integral part of this Agreement. In the
event of any inconsistencies, the following order of precedence shall
apply:

    

    
      
        	
                
                

              	
                1.

              	
                This
      Agreement (not including the
Annexes);

              

      

    

    
      	
              
              

            	
              
                2.

              

            	
              
                Annex
      A: Definitions and
Abbreviations;

              

            

    

    
      	
              
              

            	
              
                
                  3.

                

              

            	
              
                
                  Annex
      B: General Commercial
Conditions;

                

              

            

    

    
      	
              
              

            	
              
                
                  4.

                

              

            	
              
                
                  Annex
      C: General Legal
Conditions;

                

              

            

    

    
      	
              
              

            	
              
                5.

              

            	
              
                Annex
      D: Quality Assurance
Agreement;

              

            

    

    
      	
              
              

            	
              
                6.

              

            	
              
                Annex
      E: Health, Safety and Environmental
  Protection;

              

            

    

    
      	
              
              

            	
              
                7.

              

            	
              
                Annex
      F: Sample Work Order;

              

            

    

    
      	
              
              

            	
              
                8.

              

            	
              
                Work
      Order for the individual project, including documentation detailing the
      Services to be provided.

              

            

    

     

    
      	
              3.

            	
              Term
      of Agreement

            

    

    

    This
Agreement shall become effective as of February 1, 2010 (the “Effective Date”),
and shall remain in effect until the completion of the Services in any
outstanding Work Order or if no Work Order is outstanding, five (5) years
following the Effective Date, unless terminated earlier in accordance with this
Agreement as specified in Section 9 of Annex C.

    

    This
Agreement has been made out in four identical copies

    

    IN WITNESS WHEREOF, the
parties have executed this Agreement as of the Effective Date.

     

    
      
        
          	
                  Date/Place:
      August 4,
    2010

                	
                  Date/Place:
      August 4,
    2010

                

        

      

    

     

    *
The asterisk denotes that confidential portions of this exhibit have been
omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The
confidential portions have been submitted separately to the Securities and
Exchange Commission.

     

    
      
         

      

      
        3

        
          

        

      

      
         

      

    

     

    
      
        
          
            	
                    Agreement
      for the Supply of Services Relating
      to

                    Development
      Materials

                  

          

        

      

    

     

    
      
        
          
            
              
                
                  
                    
                      	
                              Novartis
      Pharma AG

                            	 
      	
                              GenVec,
      Inc.

                            
	 
      	 
      	 
      
	
                              
                                David
      Epstein

                              

                            	 
      	
                              Douglas
      J. Swirsky

                            
	
                              
                                Head
      of Novartis Pharmaceuticals

                              

                            	 
      	
                              Senior
      Vice President, Chief Financial

                            
	
                              
                                Division

                              

                            	 
      	 
      	
                              Officer and Treasurer

                            	 
      
	
                              Name
      / Function

                            	 
      	
                              Name
      / Function

                            
	 
      	 
      	 
      
	 
      	 
      	 
      	 
      	 
      
	
                              Name
      / Function

                            	 
      	
                              Name
      /
Function

                            

                    

                  

                

              

            

          

        

      

    

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

     

    
      
         

      

      
        4

        
          

        

      

      
         

      

    

    
       

      
        
          
            	
                    Agreement
      for the Supply of Services Relating
      to

                    Development
      Materials

                  

          

        

      

    

     

    Annex A : Definitions and
Abbreviations

    
The
following terms shall have the following meanings in this Agreement, whether
used in their singular or plural forms:

    

    
      	
              1.

            	
              “Adenovector”
      shall mean the following adenoviral vectors: * and any derivatives thereof
      that are *.

            

    

    

    
      	
              2.

            	
              “Affiliate”
      shall mean any corporation or other business entity controlled by,
      controlling or under common Control with a party. “Control” for the
      purposes of this definition shall mean direct or indirect beneficial
      ownership of fifty percent (50%) or more of the voting interest in an
      entity, or such other relationship as, in fact, constitutes actual
      control.

            

    

    

    
      	
              2.

            	
              “Atonal
      Vector” means an Adenovector comprising a Gene
  Fragment.

            

    

    

    
      	
              3.

            	
              “Basic
      Materials” shall mean any Drug Substance, substances, molecules,
      Excipients and other materials (including without limitation Packaging
      Materials and in-process components such as granules), which are required
      for GenVec to provide the Services.

            

    

    

    
      	
              4.

            	
              “cGMP”
      shall mean the rules concerning good manufacturing practices according to
      the current EC/PIC GMP Guidelines, the US Code of Federal Regulations, the
      laws and regulations of the European Union and the corresponding
      applicable national laws and
regulations.

            

    

    

    
      	
              5.

            	
              “Claims”
      shall have the meaning set forth in Section 12.1 of Annex
    C.

            

    

    

    
      	
              6.

            	
              “Collaboration
      Agreement” shall have the meaning provided in the recitals to this
      Agreement.

            

    

    

    
      	
              7.

            	
              “Confidential
      Information” shall have the meaning set forth in Section 14.2. of Annex
      C.

            

    

    

    
      	
              8.

            	
              “Control”
      or “Controlled” means, with respect to Intellectual Property, the
      possession of the right (whether by ownership, license or otherwise (other
      than pursuant to a license granted under this Agreement), to assign, or
      grant a license, sublicense or other right to or under, such Intellectual
      Property as provided for herein without violating the terms of any
      agreement or other arrangement with any third
  party.

            

    

    

    
      	
              9.

            	
              “Development
      Materials” shall mean any Products, drug product or placebo, including
      without limitation any substances, molecules, Excipients and materials
      contained therein, which GenVec analyzes, develops, and/or manufactures
      under this Agreement, whether a Novartis drug product or a third party
      drug product (i.e., a comparator
drug).

            

    

    

    
      	
              10.

            	
              “Drug
      Substance” shall mean the molecule or ingredient to which the
      pharmacological activity of any drug product is
  attributed.

            

    

     

    * The asterisk denotes that confidential portions of this exhibit have been
omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The
confidential portions have been submitted separately to the Securities and
Exchange Commission.

     

    
      
         

      

      
        5

        
          

        

      

      
         

      

    

     

    
      
        
          
            	
                    Agreement
      for the Supply of Services Relating
      to

                    Development
      Materials

                  

          

        

      

    

     

    
      	
              11.

            	
              “Effective
      Date” shall have the meaning set forth in Section 3 of this
      Agreement.

            

    

    

    
      	
              12.

            	
              “Equipment”
      shall mean the equipment described in Attachment D of the respective Work
      Order.

            

    

    

    
      	
              13.

            	
              “Excipient”
      shall mean any material other than the Drug Substance in a Development
      Material.

            

    

    

    
      	
              14.

            	
              “Force
      Majeure” shall have the meaning set forth in Section 18 of Annex
      C.

            

    

    

    
      	
              15.

            	
              “Gene
      Fragment” shall mean (i) an animal atonal gene or gene fragment, (ii) a
      human atonal gene or gene fragment, and (iii) nucleic acid encoding an
      atonal protein polypeptide or
peptide.

            

    

    

    
      	
              16.

            	
              “Indemnitee”
      shall have the meaning set forth in Section 12.3(a) of Annex
      C.

            

    

    

    
      	
              17.

            	
              “Indemnitor”
      shall have the meaning set forth in Section 12.3(a) of Annex
      C.

            

    

    

    
      	
              18.

            	
              “Intellectual
      Property” shall include without limitation all rights in patents, patent
      applications, including any substitutions, extensions, supplemental patent
      certificates, reissues, renewals, divisions, continuations or
      continuations-in-part thereof, trademarks, trademark applications, trade
      names, trade dress, trade secrets, inventions (whether patentable or not),
      know-how, data, results, information (including without limitation
      Technical Information), discoveries, improvements, copyrights and
      industrial designs (whether registered or
  unregistered).

            

    

    

    
      	
              19.

            	
              “JSC”
      shall mean set forth in Section 3.2 of the Collaboration
      Agreement.

            

    

     

    
      	
              20.

            	
              *“Non-Conforming
      Development Materials” shall mean Development Materials which do not
      comply with the Specifications due to GenVec’s non-compliance with the
      terms of this Agreement.

            

    

    

    
      	
              21.

            	
              “Novartis
      Data” shall have the meaning set forth in Section 11.1. of Annex
      C.

            

    

    

    
      	
              22.

            	
              “Packaging
      Material” shall mean any material employed in the packaging of a
      Development Material, whether Primary Packaging Material or Secondary
      Packaging Material. For the avoidance of doubt, outer packaging used for
      transportation or shipment only shall not be considered as Packaging
      Material.

            

    

    

    
      	
              23.

            	
              “Primary
      Packaging Material” shall mean Packaging Material which is in direct
      contact with the Development
Materials.

            

    

    

    
      	
              24.

            	
              “Products”
      mean a composition or therapy that contains, incorporates or employs
      either (a) an Atonal Vector or (b) a Gene
  Fragment.

            

    

     

    * The asterisk denotes that confidential portions of this exhibit have been
omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The
confidential portions have been submitted separately to the Securities and
Exchange Commission.

     

    
      
         

      

      
        6

        
          

        

      

      
         

      

    

    
       

      
        
          
            	
                    Agreement
      for the Supply of Services Relating
      to

                    Development
      Materials

                  

          

        

      

    
      	
              25.

            	
              “Quality
      Assurance” shall mean the sum total of the organized arrangements made
      with the purpose of ensuring that the Development Materials are of the
      quality required for their intended use and that quality systems are
      maintained.

            

    

    

    
      	
              26.

            	
              “Research
      Collaboration” shall have the meaning set forth in the Collaboration
      Agreement.

            

    

    

    
      	
              27.

            	
              “Research
      Collaboration IP” shall have the meaning set forth in the Collaboration
      Agreement.

            

    

    

    
      	
              28.

            	
              “Secondary
      Packaging Material” shall mean all Packaging Material which is not Primary
      Packaging Material.

            

    

    

    
      	
              29.

            	
              “Services”
      shall have the meaning set forth in Section 1.1. of this
      Agreement.

            

    

    

    
      	
              30.

            	
              “Specifications”
      shall mean the documents developed jointly by Novartis and GenVec
      specifying the required characteristics of the Basic Materials or the
      Development Materials to which they relate. The Specifications are
      overseen by the JSC and, with respect to the activities of the JSC, the
      governance provisions set forth in Article 3 of the Collaboration
      Agreement applies.

            

    

    

    
      	
              31.

            	
              “Technical
      Information” shall mean all information and results to the extent
      applicable to the Development Materials or to the performance of the
      Services hereunder, whether such information and results are provided or
      generated by Novartis or GenVec.

            

    

    

    
      	
              32.

            	
              “Termination
      Date” shall have the meaning set forth in Section 10.2 of Annex
      C.

            

    

    

    
      	
              33.

            	
              “Work
      Order” shall mean the statement of work issued by Novartis under this
      Agreement, and all documents which are incorporated into the statement of
      work by reference, including for example and without limitation any offer
      made by GenVec, Technical Information, Specifications, and any other
      information detailing the Services to be
  provided.

            

    

     

    * The asterisk denotes that confidential portions of this exhibit have been
omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The
confidential portions have been submitted separately to the Securities and
Exchange Commission.

     

    
      
         

      

      
        7

        
          

        

      

      
         

      

    

     

    
      
        
          	
                  Agreement
      for the Supply of Services Relating
      to

                  Development
      Materials

                

        

      

    

    

    Annex
B : General Commercial Conditions

    

    
      	
              1.

            	
              Commercial
      Conditions

            

    

    

    
      	
              1.1

            	
              The
      commercial arrangements for the provision of any Services shall be set
      forth in Work Orders.  Work Orders and the attachments thereto
      shall be arranged as follows:

            

    

    

    
      	
               

            	
              (a)

            	
              Cover
      Sheet issued by Novartis

            

    

    
      	
               

            	
              (b)

            	
              Description
      of the Work

            

    

    
      	
               

            	
              (c)

            	
              Description
      of Work

            

    

    
      	
               

            	
              (e)

            	
              Payment
      and Delivery Schedule as agreed between the
  parties

            

    

    
      	
               

            	
              (f)

            	
              Description
      of Equipment

            

    

    
      	
               

            	
              (g)

            	
              Contact
      persons and addresses as provided by the respective
  party

            

    

    

    
      This list
may not be exhaustive as the actual work will need some additional information
which could be provided by means of attachments to a specific Work
Order.

    

    

    A sample
Work Order is attached hereto as Annex F.

    

    
      	
              1.2

            	
              Except
      as otherwise agreed between the parties, the total cost to Novartis for
      the completion of the Services by GenVec shall be the amount set forth in
      the applicable Work Order, plus any applicable VAT which may become due
      under a Work Order.  Work Orders shall not become effective
      until executed by both parties.

            

    

     

    
      	
              1.3

            	
              Except
      as otherwise agreed by the parties in writing, GenVec shall not provide
      any Services prior to the execution of a Work Order by both parties or a
      modification of a Work Order, whichever is
  applicable.

            

    

     

    Unless
otherwise agreed to in writing by GenVec and Novartis, all costs and rates
outlined in a Work Order shall remain firm for the duration of the provision of
Services under that particular Work Order; provided, however, if any
amendments are to be made to the terms of a Work Order — including to the costs
– GenVec shall not proceed with such Work Order until such time that Novartis
and GenVec agree on the revised terms of and execute such Work Order in
accordance with Section 13 of Annex C.

    

    
      	
              2.

            	
              Reimbursement
      of Expenses

            

    

    

    
      Should
any Work Order state that Novartis will reimburse GenVec for out-of-pocket
expenses incurred by GenVec in supplying Services under this Agreement, then
Novartis shall do so, provided that the expenses are either described in the
Work Order or are necessary to the performance of the Services hereunder, that
they are reasonable (i.e. Novartis will not reimburse luxury or first class
travel or accommodation) and that they have been approved in advance by Novartis
in writing.

    

     

    * The asterisk denotes that
confidential portions of this exhibit have been omitted in reliance on Rule
24b-2 of the Securities Exchange Act of 1934. The confidential portions have
been submitted separately to the Securities and Exchange Commission.

     

    
      
        
        

      

      
        8

        
          

        

      

      
        
        

      

    

     

    
      
        
          	
                  Agreement
      for the Supply of Services Relating
      to

                  Development
      Materials

                

        

      

    

     

    
      	
              3.

            	
              Invoicing
      and Payment

            

    

    

    
      	
              3.1

            	
              GenVec
      shall send its invoices *.

            

    

     

    
      	
              3.2

            	
              GenVec
      shall send its invoices to the address specified on the respective Work
      Order, or to such other address as may be advised by Novartis in writing
      from time to time.

            

    

    

    
      	
              3.3

            	
              Invoices
      shall specify the Work Order number, the project to which the invoice
      relates, the Services performed the amount payable, the VAT rate and
      amount if applicable, the fee breakdown, the dates on which the Services
      were performed, receipts for expenses claimed, and GenVec’s bank
      details.

            

    

    

    
      	
              3.4

            	
              In
      consideration of the satisfactory performance of the Services, Novartis
      shall pay invoices within * of
receipt.

            

    

    

    
      	
              3.5

            	
              Novartis
      shall be liable only for those value-added taxes imposed upon GenVec by
      operation of law. Novartis may require GenVec to provide Novartis with
      documentation satisfactory to Novartis establishing the liability for such
      taxes.

            

    

     

    
      	
              4.

            	
              Financial
      Auditing

            

    

    

    
      At the
written request of Novartis, giving a reasonable period of notice (but not less
than * prior to the proposed audit date), GenVec shall make available to
Novartis and/or its auditors for inspection all documents relating to finances
and associated with the invoiced Services for the purpose of ensuring the
accuracy of all fees and expenses invoiced to Novartis.  Unless there
is reasonable cause for an audit, Novartis shall not conduct an audit more
frequently than *, no records may be audited more * years following the period
to which the records relate.  Any audit by Novartis shall be at
Novartis’ sole cost and expense, unless as a result of the audit is determined
that GenVec overcharged Novartis by more than * of the amount properly
determined.  Regardless, GenVec shall promptly pay to Novartis, or
offset from any amounts owed by Novartis, the amount of any overcharge
determined by audit.

    

    

    
      	
              5.

            	
              Delivery
      Conditions

            

    

    

    GenVec shall deliver Development
Materials DDU (INCOTERMS 2000)  to Novartis Pharmaceuticals
Corporation, Drug Supply Management, One Health Plaza, East Hanover, NJ
07936-1080, USA or as otherwise directed in writing.

     

    * The asterisk denotes that
confidential portions of this exhibit have been omitted in reliance on Rule
24b-2 of the Securities Exchange Act of 1934. The confidential portions have
been submitted separately to the Securities and Exchange Commission.

     

    
      
        
        

      

      
        9

        
          

        

      

      
        
        

      

    

    
       

      
        
          
            	
                    Agreement
      for the Supply of Services Relating
      to

                    Development
      Materials

                  

          

        

      

    

     

    Annex
C : General Legal Conditions

    
      	
              1.

            	
              Standard
      of Services and Compliance with Regulatory
  Requirements

            

    

     

    
      	
              1.1

            	
              GenVec
      shall perform the Services:

            

    

    

    
      
        	
                
                

              	
                (a)

              	
                in
      compliance with the provisions of this Agreement (including without
      limitation any Work Order issued
hereunder),

              

      

    

    
      	
              
              

            	
              
                (b)

              

            	
              
                in
      a professional manner;

              

            

    

    
      	
              
              

            	
              
                (c)

              

            	
              
                in
      conformance with that level of care and skill ordinarily exercised by
      other professional suppliers of materials similar to the Development
      Materials;

              

            

    

    
      	
              
              

            	
              
                (d)

              

            	
              
                in
      full compliance with all applicable local, state and federal laws and
      regulations and other regulatory requirements, including without
      limitation the regulations promulgated by the FDA and any equivalent
      regulatory agencies;

              

            

    

    
      	
              
              

            	
              
                (e)

              

            	
              
                if
      applicable, in full compliance with
cGMP;

              

            

    

    
      	
              
              

            	
              
                (f)

              

            	
              
                in
      full compliance with the
Specifications;

              

            

    

    
      	
              
              

            	
              
                (g)

              

            	
              
                if
      applicable, in full compliance with all applicable EU Directives,
      including without limitation Commission Directive 2003/94/EC of 8 October
      2003 laying down the principles and guidelines of good manufacturing
      practice in respect of medicinal products for human use and
      investigational medicinal products for human use, including without
      limitation Annex 13 of such
Directive.

              

            

    

     

    
      	
              1.2

            	
              GenVec
      shall perform the Services exclusively in its own facilities and for cGMP
      acitivites using fully qualified equipment audited and approved by
      Novartis, except that any Services which have been sub-contracted in
      accordance with Section 16 of Annex C shall be performed exclusively in
      the facilities of the sub-contractor or as otherwise set forth in the
      applicable Work Order.

            

    

    

    
      	
              1.3

            	
              Novartis
      agrees to make an investment in the Equipment, which GenVec agrees to
      purchase and which GenVec shall own and hold legal title to under the
      terms of this Agreement.

            

    

    

    
      	
              1.4

            	
              Payment
      for the Equipment will be made by Novartis within * of receipt of invoice.
      Invoices shall be submitted by GenVec as specified and scheduled in
      Attachment D of the respective Work Order and in correspondence with
      Section 3, Annex B.

            

    

    

    
      	
              1.5

            	
              GenVec
      acknowledges and agrees that the total payments for the Equipment shall
      not exceed the amount specified in Attachment D of the respective Work
      Order and in no circumstances shall Novartis be liable to pay any
      additional sum above this amount. In the event the Equipment costs
      subsequently increase above such amount due solely to increased raw
      material costs, GenVec and Novartis may discuss in good faith possible
      payment of additional costs by Novartis, however, there is no obligation
      upon Novartis to do so or to pay any additional amount. For the avoidance
      of doubt, subject to any applicable provisions of the Agreement, Novartis
      shall not be liable for any maintenance or repair costs or any other costs
      associated with the Equipment.

            

    

    

    
      	
              1.6

            	
              Novartis
      takes no responsibility for the delivery, insurance, carriage or
      maintenance of the Equipment which shall be arranged by GenVec at its own
      cost and risk.

            

    

     

    * The asterisk denotes that confidential portions of this exhibit have been
omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The
confidential portions have been submitted separately to the Securities and
Exchange Commission.

     

    
      
         

      

      
        10

        
          

        

      

      
         

      

    

     

    
      
        
          
            	
                    Agreement
      for the Supply of Services Relating
      to

                    Development
      Materials

                  

          

        

      

    

     

    
      	
              1.7

            	
              The
      GenVec shall maintain the Equipment, at its sole cost, in good working
      order, free of third party liens or other encumbrances of
      GenVec.

            

    

    

    
      	
              1.8

            	
              The
      GenVec shall, at its cost, insure the Equipment, against casualty to the
      same extent, including deductibles, as GenVec insures other comparable
      equipment owned by GenVec, it being agreed and understood that such
      insurance may be part of GenVec’s standard insurance
    coverage.

            

    

    

    
      	
              1.9

            	
              The
      GenVec agrees that the Equipment shall be dedicated and, accordingly, used
      solely in connection with the respective Work Order, and that the
      Equipment shall only be used as permitted under this Agreement and the
      respective Work Order and for no other purpose (unless otherwise directed
      by Novartis in writing), including any projects or services for any third
      parties or for any other internal
purpose.

            

    

    

    
      	
              1.10

            	
              Upon
      termination of this Agreement, or of any Work Order, as the case may be,
      GenVec shall fully cooperate with Novartis with regard to the disposition
      or return of the Equipment (as directed by Novartis in its sole
      discretion), which may include, without limitation, providing Novartis (or
      their designated agents) with reasonable access to GenVec’s facilities to
      take possession of and remove the Equipment, whereupon full legal right
      and title to the Equipment shall automatically pass to Novartis without
      any further payments from Novartis to
GenVec.

            

    

     

    
      
        	
                2.

              	
                Exchange
      of Information

              

      

    

    

    
      	
              2.1

            	
              The
      parties shall exchange information on all matters pertaining to the
      Services performed under this Agreement, and GenVec shall inform Novartis
      promptly regarding all matters  of which it is aware and which
      could impact materially on the Services, including without limitation
      matters of a scientific, regulatory or legal
  nature.

            

    

    

    
      	
              2.2

            	
              GenVec
      shall provide to Novartis all information and documentation reasonably
      requested by Novartis and within the scope of the Services and shall
      render any other assistance reasonably requested, to enable Novartis
      to:

            

    

    

    
      
        	
              	
                (a)

              	
                obtain
      from any regulatory authority any approval, authorization or license in
      connection with the Development
Materials;

              

      

    

    
      	
            	
              
                (b)

              

            	
              
                comply
      with any of its legal, regulatory and/or contractual obligations or any
      request by any regulatory authority;
  and/or

              

            

    

    
      	
            	
              
                (c)

              

            	
              
                determine
      whether any Services have been performed in accordance with this
      Agreement.

              

            

    

    

    
      	
              3.

            	
              Representations
      and Warranties

            

    

    

    
      	
              3.1

            	
              Except
      as set forth in this Section 3 of this Annex C, including without
      limitation the warranty set forth in Section 3.2 of this Annex C, GenVec
      makes no warranties, express or implied, regarding the Development
      Materials, including any warranties of merchantability or fitness for a
      particular purpose.

            

    

     

    * The asterisk denotes that confidential portions of this exhibit have been
omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The
confidential portions have been submitted separately to the Securities and
Exchange Commission.

     

    
      
         

      

      
        11

        
          

        

      

      
         

      

    

    
       

      
        
          
            	
                    Agreement
      for the Supply of Services Relating
      to

                    Development
      Materials

                  

          

        

      

    

     

    
      	
              3.2

            	
              GenVec
      represents and warrants that the Development Materials will comply with
      the Specifications and that GenVec and its Affiliates will perform the
      Services and all their obligations in accordance with this Agreement and
      in accordance with all applicable laws, regulations, directives and
      guidelines.

            

    

     

    * The asterisk denotes that confidential portions of this exhibit have been
omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The
confidential portions have been submitted separately to the Securities and
Exchange Commission.

     

    
      
         

      

      
        12

        
          

        

      

      
         

      

    

     

    
      
        
          	
                  Agreement
      for the Supply of Services Relating
      to

                  Development
      Materials

                

        

      

    

    

    
      	
              3.3

            	
              Each
      party represents and warrants that
:

            

    

    

    
      
        	
              	
                (a)

              	
                it
      is a corporation duly organized, validly existing and in good standing
      under the laws of the state in which it is
  incorporated;

              

      

    

    
      	
            	
              
                (b)

              

            	
              
                it
      has the corporate power and authority and the legal right to enter into
      this Agreement and to perform its obligations
    hereunder,

              

            

    

    
      	
            	
              
                (c)

              

            	
              
                it
      has taken all necessary corporate action on its part to authorize the
      execution and delivery of this Agreement and the performance of its
      obligations hereunder;

              

            

    

    
      	
            	
              
                (d)

              

            	
              
                it
      knows of no contract, agreement, promise, undertaking or other fact or
      circumstance which would prevent the performance of the obligations under
      this Agreement;

              

            

    

    
      	
            	
              
                (e)

              

            	
              
                this
      Agreement has been duly executed and delivered on behalf of such party,
      and constitutes a legal, valid, binding obligation, enforceable against
      such party in accordance with its terms, subject to the general principles
      of equity and to bankruptcy, insolvency, moratorium and other laws
      affecting the enforcement of creditors’ rights
      generally.

              

            

    

    
      	
            	
              
                (f)

              

            	
              
                the
      execution and delivery of this Agreement and the performance of the
      party’s obligations hereunder do not conflict with or violate any
      requirement of applicable laws or regulations, and do not conflict with,
      or constitute a default under, any contractual obligation of such
      party

              

            

    

    

    
      	
              3.4

            	
              GenVec
      represents and warrants that it, together with any of its Affiliates which
      are permitted or required to perform Services under this Agreement, and
      any subcontractors which are permitted in accordance with Section 16 of
      this Annex C, have the expertise, necessary equipment, facilities,
      materials and qualified labour force to provide the Services
      hereunder.

            

    

     

    
      	
              4.

            	
              Regulatory
      Approvals, Authorisations and
Permits

            

    

    

    
      	
              4.1

            	
              GenVec
      undertakes to obtain, hold and comply with, at its own expense, all
      necessary regulatory approvals, authorizations and permits required to
      perform the Services under this Agreement from the authorities of the
      country or countries where such Services shall be performed, including but
      not limited to all necessary authorizations and permits for the
      acquisition, storage and handling of materials. GenVec shall provide to
      Novartis upon Novartis’ request copies of all such regulatory approvals,
      authorizations and permits.  GenVec shall inform Novartis
      promptly in the event any such regulatory approval, authorization or
      permit is not obtained or is withdrawn. For the avoidance of doubt, GenVec
      shall ensure that any and all sub-contractors of GenVec comply with this
      obligations.

            

    

     

    
      	
              5.

            	
              Basic
      Materials

            

    

    

    
      	
              5.1

            	
              In
      the event that Novartis supplies any Basic Materials to GenVec, such Basic
      Materials shall remain the exclusive property of Novartis and shall be
      identified as such in GenVec’s
books.

            

    

     

    * The asterisk denotes that confidential portions of this exhibit have been
omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The
confidential portions have been submitted separately to the Securities and
Exchange Commission.

     

    
      
         

      

      
        13

        
          

        

      

      
         

      

    

     

    
      
        
          	
                  Agreement
      for the Supply of Services Relating
      to

                  Development
      Materials

                

        

      

    

     

    
      	
              5.2

            	
              In
      the event that Novartis supplies any Basic Material to GenVec, all risks
      of loss and damage therein shall pass to GenVec upon delivery to
      GenVec.

            

    

    

    
      	
              5.3

            	
              In
      the event that Novartis supplies any Basic Material to GenVec, GenVec
      shall promptly check the identity and integrity of the Basic Materials. If
      GenVec establishes that such Basic Material is not in conformity with the
      agreed Specifications, the following shall
  apply:

            

    

    

    
      
        	
              	
                (a)

              	
                GenVec
      shall inform Novartis in writing promptly upon discovery of such
      defect;

              

      

    

    
      	
            	
              
                (b)

              

            	
              
                At
      Novarti’s expense, GenVec shall return the defective Basic Material to
      Novartis or destroy it, as per Novartis’ written instructions. In no event
      shall GenVec destroy or dispose of any Basic Material without Novartis’
      prior written consent;

              

            

    

    
      	
            	
              
                (c)

              

            	
              
                Novartis
      shall as soon as reasonably possible replace such defective Basic Material
      with Basic Material meeting the agreed
    Specifications;

              

            

    

    
      	
            	
              
                (d)

              

            	
              
                In
      the event it is established that the deviation from the agreed
      Specifications occurred after delivery of the defective Basic Material to
      GenVec and through the fault of GenVec, such Basic Material shall be
      replaced at GenVec’s expense, including the costs for transportation, and,
      notwithstanding the provisions of subsection (b) above,  GenVec
      shall bear sole responsibility for all reasonable costs associated with
      any testing, return and/or destruction of the defective Basic Material;
      and

              

            

    

    
      	
            	
              
                (e)

              

            	
              
                In
      the event it is established that the deviation from the agreed
      Specifications occurred prior to delivery of the defective Basic Material
      to GenVec or other than through the fault of GenVec, such Basic Material
      shall be replaced at Novartis’ expense, including the costs for
      transportation, and Novartis shall bear sole responsibility for all
      reasonable costs associated with any testing, return and/or destruction of
      the defective Basic Material.

              

            

    

    

    
      	
              5.4

            	
              GenVec
      shall not use or analyse any Basic Materials supplied by Novartis, or
      transfer any Basic Materials to any third party, for any purpose other
      than the performance of its obligations under this Agreement in accordance
      with its terms.

            

    

     

    * The asterisk denotes that confidential portions of this exhibit have been
omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The
confidential portions have been submitted separately to the Securities and
Exchange Commission.

     

    
      
         

      

      
        14

        
          

        

      

      
         

      

    

     

    
      
        
          	
                  Agreement
      for the Supply of Services Relating
      to

                  Development
      Materials

                

        

      

    

    

    
      	
              5.5

            	
              In
      the event of an unresolved dispute as to the conformity of any Basic
      Material provided by Novartis with the relevant Specification, the parties
      shall, within 30 (thirty) days, promptly appoint a mutually acceptable
      independent laboratory to undertake the relevant testing. The findings of
      such laboratory shall be conclusive and binding upon the parties. The
      parties shall ensure that such independent laboratory is bound by
      obligations of confidentiality and non-use no less strict than those set
      out herein. All fees and expenses of the said laboratory shall be borne
      solely by the party which is unsuccessful in the
  dispute.

            

    

    

    
      	
              5.6

            	
              Upon
      request by Novartis, which may be made at any time at reasonable
      intervals, GenVec shall provide to Novartis an inventory of Basic
      Materials in GenVec’s possession.

            

    

     

    
      	
              6.

            	
              Development
      Materials

            

    

    

    
      	
              6.1

            	
              Development
      Materials shall be the exclusive property of Novartis at all times. The
      GenVec shall have no rights herein.

            

    

    

    
      	
              6.2

            	
              GenVec
      shall bear all risks of loss of and damage to the Development Materials,
      until they are delivered to Novartis in accordance with this Agreement, at
      which time such risk shall pass to
Novartis.

            

    

    

    
      	
              6.3

            	
              GenVec
      shall not use or analyse any Development Materials, or transfer any such
      Development Materials to any third party, for any purpose other than the
      performance of its obligations under this Agreement in accordance with its
      terms.

            

    

     

    
      	
              7.

            	
              Right
      of Rejection

            

    

    

    
      	
              7.1

            	
              If
      GenVec delivers any Non-Conforming Development Materials, or otherwise
      materially fails to perform any Services in accordance with this
      Agreement, Novartis shall inform GenVec thereof promptly upon discovery,
      but no later than * after receipt of the Non-Conforming Development
      Materials. Novartis shall notify GenVec of Latent Defects (i.e. defects
      which are not reasonably discoverable by routine quality control measures)
      within * from their discovery. Payment of the Development Materials shall
      not be deemed to imply an acceptance of the Development
      Materials.

            

    

     

    * The asterisk denotes that confidential portions of this exhibit have been
omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The
confidential portions have been submitted separately to the Securities and
Exchange Commission.

     

    
      
         

      

      
        15

        
          

        

      

      
         

      

    

     

    
      
        
          	
                  Agreement
      for the Supply of Services Relating
      to

                  Development
      Materials

                

        

      

    

    

    
      	
              7.2

            	
              Without
      prejudice to any additional rights arising from the delivery of
      Non-Conforming Development Materials, Novartis shall have the right to
      reject any Non-Conforming Development Materials or any batch containing
      Non-Conforming Development Materials. Promptly after receiving notice
      under Section 7.1 above, GenVec shall, free of charge, replace such
      rejected Development Materials with Development Materials that conform
      with the Specifications in accordance with this
      Agreement.  GenVec shall reimburse Novartis and its Affiliates
      for all reasonable expenses incurred from the return or disposal of
      Non-Conforming Development Materials and shall reimburse Novartis at cost
      for any Basic Material which are required to manufacture the replacement
      Development Materials. * The provisions of this Section 7.2 are the sole
      and exclusive remedy of Novartis with respect to any Non-Conforming
      Development Materials.

            

    

    

    
      	
              7.3

            	
              In
      the event of an unresolved dispute as to the conformity of any Development
      Material with the relevant Specification, the parties shall follow the
      procedure set forth in Section 5.5 of this Annex
  C.

            

    

     

    
      	
              8.

            	
              Inspections/Audits

            

    

    

    
      	
              8.1

            	
              Novartis
      will have the right, and GenVec shall permit or assure that Novartis has
      the right, at reasonable intervals and on reasonable prior notice, to
      audit and inspect the facilities and the equipment used for the
      performance of the Services under this Agreement.  Such
      inspections may include cGMP inspections and system audits and audit
      compliance with the terms of this Agreement. If at any time GenVec is
      found not to be in compliance with this Agreement, cGMP guidelines or any
      other applicable legal or regulatory requirement, GenVec will remedy the
      issues by complying with the corrective actions required pursuant to the
      Novartis audit observations (where agreement is reached on such
      observations), within the time frame provided for in the corrective
      actions request at its own costs, if not agreed otherwise by the parties
      in writing.

            

    

    

    
      	
              8.2

            	
              The
      GenVec shall permit authorized officials of any regulatory authority or
      other competent governmental agencies to inspect its facilities and
      equipment used to perform the
Services.

            

    

    

    
      	
              8.3

            	
              The
      rights of inspection set forth in this Section 8 shall survive the
      termination of this Agreement as per the terms of the Quality Assurance
      Agreement.

            

    

     

    
      	
              9.

            	
              Term
      and Termination

            

    

    

    
      	
              9.1.

            	
              The
      term of this Agreement is set forth in Section 3 of this Agreement.
      Notwithstanding the foregoing, should any Work Order entered into during
      the term of the Agreement require Services to be performed after the
      expiry or termination for whatever reason of this Agreement, the terms of
      this Agreement shall remain in effect with respect to such Work Order
      until the Work Order has been terminated or the Services thereunder have
      been completed.

            

    

     

    * The asterisk denotes that confidential portions of this exhibit have been
omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The
confidential portions have been submitted separately to the Securities and
Exchange Commission.

     

    
      
         

      

      
        16

        
          

        

      

      
         

      

    

    
       

      
        
          
            	
                    Agreement
      for the Supply of Services Relating
      to

                    Development
      Materials

                  

          

        

      

    

     

    
      	
              9.2

            	
              Novartis
      may terminate this Agreement and/or any Work Order issued hereunder by
      notice in writing with immediate effect in the event
  that:

            

    

    

    
      
        	
              	
                (a)

              	
                Novartis
      determines that it cannot use the respective Development Materials for any
      reason including without limitation for any medical, scientific, safety,
      commercial, regulatory or legal reason;
or

              

      

    

    

    
      
        	
              	
                (b)

              	
                GenVec
      is a “Breaching Party” under Section 13.2 of the Collaboration Agreement,
      and Novartis is entitled to terminate the Collaboration Agreement under
      Section 13.2(b) or 13.2(c) of the Collaboration Agreement.  For
      purposes of clarity, Novartis shall not be required to actually terminate
      the Collaboration Agreement pursuant to Section 13.2(b) or terminate any
      section thereof pursuant to Section 13.2(c) of the Collaboration Agreement
      in order to invoke its right to terminate this Agreement and/or any Work
      Order issued hereunder.

              

      

    

    

    
      	
              9.3

            	
              Either
      party may terminate this Agreement and/or any Work Order issued hereunder
      by notice in writing with immediate effect and without prejudice to its
      other rights and remedies if:

            

    

    

    
      
        	
              	
                (a)

              	
                a
      petition in bankruptcy is filed by or against the other party, or a
      receiver, trustee or liquidator is appointed for any of the assets of the
      other party;

              

      

    

    

    
      	
            	
              
                (b)

              

            	
              
                the
      other party files a petition for reorganization under any bankruptcy,
      reorganization or other similar law, or makes an assignment for the
      benefit of its creditors;

              

            

    

    

    
      	
            	
              
                (c)

              

            	
              
                the
      other party is adjudged bankrupt or insolvent by any court of competent
      jurisdiction; or

              

            

    

    

    
      	
            	
              
                (d)

              

            	
              
                the
      other party is in material breach of its obligations under the Agreement,
      which breach remains uncured for * following receipt of written notice
      specifying the breach, unless such breach is cured during such period, or
      if such breach can not be cured during such * period, and the breaching
      party has commenced reasonable efforts during this period to cure such
      breach as promptly as
practicable.

              

            

    

     

    
      	
              10.

            	
              Rights
      and Obligations upon Termination

            

    

    

    
      	
              10.1

            	
              Upon
      the termination of this Agreement and/or any Work Order, GenVec
      shall:

            

    

    

    
      
        	
              	
                (a)

              	
                promptly
      refrain from using or sharing with any third party under this Agreement
      any Confidential Information of
Novartis;

              

      

    

     

    * The asterisk denotes that confidential portions of this exhibit have been
omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The
confidential portions have been submitted separately to the Securities and
Exchange Commission.

     

    
      
         

      

      
        17

        
          

        

      

      
         

      

    

    
       

      
        
          
            	
                    Agreement
      for the Supply of Services Relating
      to

                    Development
      Materials

                  

          

        

      

    

     

    
      
        	
              	
                (b)

              	
                at
      the request of Novartis, return any unused Basic Materials supplied by
      Novartis;

              

      

    

    

    
      	
            	
              
                (c)

              

            	
              
                at
      the request of Novartis, supply to Novartis all Development Materials
      whether in semi-finished or finished form, including all Technical
      Information;

              

            

    

    

    
      (d)
Upon
Novartis request and, return the Equipment in accordance with Section
1.10

    

    

    
      	
            	
              
                (e)

              

            	
              
                retain
      all retention samples and documentation for the period specified in the
      Quality Assurance Agreement, and shall not dispose of any such samples and
      documentation at the end of such period without advising Novartis in
      writing and offering Novartis the opportunity to take possession of such
      samples and documentation;

              

            

    

    

    
      	
            	
              
                (f)

              

            	
              
                promptly
      return to Novartis all documents containing Confidential Information of
      Novartis (including, but not limited to, any reproduction, notes,
      summaries, print-outs and copies of information stored in electronic or
      computerized systems) and any other items put at GenVec’s disposal by
      Novartis under this
Agreement;

              

            

    

    

    
      	
            	
              
                (g)

              

            	
              
                any
      and  all Confidential Information of Novartis that is stored in
      electronic or computerized systems under the control of GenVec that can
      for technical reasons not be returned shall be deleted without delay;
      and

              

            

    

    

    
      	
            	
              
                (g)

              

            	
              
                provide
      reasonable assistance to Novartis, at Novartis’ cost, in transferring the
      information required for Novartis to perform the Services itself or to
      out-source the Services to a third party. Novartis shall reimburse
      GenVec’s reasonable expenses incurred in connection therewith provided
      Novartis has approved such expenses in writing in
      advance.

              

            

    

    

    
      	
              10.2

            	
              Except
      in the case of termination under Section 9.3 above, in which case Novartis
      shall owe GenVec no further obligation, upon the effective date of
      termination of any Work Order and/or the Agreement (the “Termination
      Date”), GenVec shall conduct an accounting in accordance with the terms of
      this Agreement, subject to verification and approval by Novartis. Within *
      of Novartis’ receipt of reasonable documentation setting forth the results
      of such accounting, Novartis shall make payment to GenVec
    for:

            

    

    

    
      
        	
              	
                (a)

              	
                all
      Services properly rendered and moneys  expended by GenVec in
      accordance with the terms of this Agreement until the Termination Date and
      not yet paid for; and

              

      

    

    

    
      
        	
              	
                (b)

              	
                reasonable
      non-cancelable obligations properly incurred to perform the Services
      pursuant to any Work Order prior to receipt of notice of termination of
      that Work Order, unless Novartis objects to any such charge, in which case
      the parties shall use best efforts to expeditiously resolve any
      disagreement.

              

      

    

    

    Further-reaching
claims are precluded. In particular, Novartis shall not be required to pay any
compensation due to the termination of the Agreement and/or a Work Order to
GenVec.

     

    * The asterisk denotes that confidential portions of this exhibit have been
omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The
confidential portions have been submitted separately to the Securities and
Exchange Commission.

     

    
      
         

      

      
        18

        
          

        

      

      
         

      

    

     

    
      
        
          
            	
                    Agreement
      for the Supply of Services Relating
      to

                    Development
      Materials

                  

          

        

      

    

     

    
      	
              10.3

            	
              GenVec
      shall return to Novartis within * of the Termination Date any funds
      advanced to it but not expended or irrevocably obligated by GenVec in
      pursuance of its obligations under this Agreement prior to the Termination
      Date.

            

    

    

    
      	
              10.4

            	
              Upon
      any termination of this Agreement and/or any Work Order, all outstanding
      rights and obligations between the parties arising from or in connection
      with this Agreement and/or the relevant Work Order shall immediately
      terminate, except:

            

    

    

    
      
        	
              	
                (a)

              	
                any
      liabilities and obligation that matured prior to the Termination
      Date;

              

      

    

    

    
      	
            	
              
                (b)

              

            	
              
                the
      following provisions of this Annex C, which shall survive the termination
      of this Agreement: Section 3 (Representations and Warranties), 8
      (Inspections and Audits), 9 (Term and Termination), 10 (Rights and
      Obligations upon Termination), 11 (Intellectual Property), 12
      (Indemnifications and Liabilities), 14 (Confidentiality and Non-Use), 19
      (Governing Law and Venue) and 24 (Publicity and Press Releases);
      and

              

            

    

    

    
      	
            	
              
                (c)

              

            	
              
                any
      other provision which, by its terms, is understood to survive the
      termination or expiration of this
  Agreement.

              

            

    

    

    
      	
              10.5

            	
              Termination
      of this Agreement shall be without prejudice to any claim or right of
      action of either party against the other party for any prior breach of
      this Agreement.

            

    

    

    
      	
              11.

            	
              Intellectual
      Property

            

    

    

    
      	
              11.1

            	
              All
      information, data and writings, including without limitation all Technical
      Information and all information relating to Basic Materials and/or
      Development Materials, provided to GenVec by and/or on behalf of Novartis
      in connection with this Agreement, in any form whatsoever (the “Novartis
      Data”), shall remain the property of Novartis. GenVec shall acquire no
      right, title or interest in the Novartis Data pursuant to this
      Agreement.

            

    

    

    
      	
              11.2

            	
              Neither
      party shall acquire, pursuant to this Agreement, any right, title or
      interest in the Intellectual Property of the other party which existed
      prior to the Effective Date.

            

    

    

    
      	
              11.3

            	
              Subject
      to Section 11.4 below, all Intellectual Property generated or derived by
      GenVec, its employees or collaborators in the performance of the Services
      or otherwise in connection with this Agreement shall be the exclusive
      property of Novartis, who shall be free to dispose of it as it sees fit.
      GenVec shall have no rights therein. All Intellectual Property generated
      or derived by GenVec’s employees and/or collaborators in connection with
      this Agreement shall be promptly notified to Novartis and all rights to
      any such Intellectual Property shall be assigned to Novartis or its
      designee.

            

    

     

    
      	
              11.4

            	
              All
      Intellectual Property generated or derived by GenVec in the performance of
      the Services or otherwise in connection with this Agreement, to the extent
      that it is specific to GenVec’s own manufacturing processes, ,
      Adenovectors, or to methodology independently developed by GenVec, and
      does not relate to any Atonal Vectors, Gene Fragments, Products, Basic
      Materials, Development Materials, Technical Information, or to other
      Confidential Information of Novartis, shall be the exclusive property of
      GenVec, who shall be free to dispose of it as it sees fit. Novartis and
      its Affiliates shall have a non-exclusive, world-wide, royalty-free, fully
      paid-up, transferable, perpetual, irrevocable, license, with the right to
      grant sub-licenses, to use and exploit all Intellectual Property falling
      within this Section 11.4.

            

    

     

    * The asterisk denotes that
confidential portions of this exhibit have been omitted in reliance on Rule
24b-2 of the Securities Exchange Act of 1934. The confidential portions have
been submitted separately to the Securities and Exchange Commission.

     

    
      
        
        

      

      
        19

        
          

        

      

      
        
        

      

    

     

    
      
        
          
            	
                    Agreement
      for the Supply of Services Relating
      to

                    Development
      Materials

                  

          

        

      

    

     

    
      	
              11.5

            	
              GenVec
      shall promptly execute all documents and take all such other action as may
      be reasonably requested by Novartis in order to permit Novartis to obtain
      the benefit of its rights under this Agreement, and shall cause any
      employees and/or collaborators to take such action. GenVec shall make
      available all relevant data in electronic form, as well as samples of
      materials obtained in the course of or as a result of performing the
      Services.

            

    

    

    
      	
              11.6

            	
              At
      the request of Novartis, after completion of the Services pursuant to any
      Work Order, GenVec shall return to Novartis all Novartis Data, Basic
      Materials and all Technical Information and other Confidential Information
      of Novartis. GenVec may keep one copy of all such returned information for
      records purposes only.

            

    

    

    
      	
              11.7

            	
              GenVec
      represents and warrants that it owns or has the right to use all its
      Intellectual Property which it shall use to perform the Services pursuant
      to any Work Order executed
hereunder.

            

    

    

    
      	
              11.8

            	
              Novartis
      makes no warranties express or implied, regarding fitness for any purpose
      of any information or material owned or supplied by Novartis under this
      Agreement, or non-infringement of third party’s Intellectual
      Property.

            

    

    

    
      	
              11.9

            	
              Should
      GenVec become aware of any infringement of Novartis’ or any third party’s
      Intellectual Property rights relating to any Development Materials or any
      manufacturing process, GenVec shall promptly notify Novartis thereof in
      writing.

            

    

     

    
      	
              12.

            	
              Indemnification
      and Liabilities

            

    

    

    
      	
              12.1

            	
              The
      GenVec shall be liable for and shall indemnify and hold Novartis and its
      Affiliates, and their officers, directors and employees, harmless against
      any and all third party liabilities, claims, damages, losses, costs and
      expenses, including reasonable attorney’s fees (collectively “Claims”)
      incurred:

            

    

    

    
      
        	
              	
                (a)

              	
                resulting
      from the use of any Non-Conforming Development Materials delivered by
      GenVec;

              

      

    

    

    
      	
            	
              
                (b)

              

            	
              
                resulting
      from any breach of this Agreement by GenVec or its Affiliates or
      sub-contractors;

              

            

    

    

    
      	
            	
              
                (c)

              

            	
              
                resulting
      from the handling, storage, disposal or arrangement for disposal by GenVec
      of any products, supplies or other materials used in connection with the
      Agreement; or

              

            

    

     

    * The asterisk denotes that confidential portions of this exhibit have been
omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The
confidential portions have been submitted separately to the Securities and
Exchange Commission.

     

    
      
         

      

      
        20

        
          

        

      

      
         

      

    

     

    
      
        
          
            	
                    Agreement
      for the Supply of Services Relating
      to

                    Development
      Materials

                  

          

        

      

    

     

    
      
        	
              	
                (d)

              	
                resulting
      from GenVec’s willful misconduct or negligence in respect of the
      performance or failure to perform any of its obligations under this
      Agreement.

              

      

    

    

    
      	
              12.2

            	
              Novartis
      shall be liable for and shall indemnify and hold GenVec and its
      Affiliates, and their officers, directors and employees, harmless against
      any Claim incurred;

            

    

    

    
      
        	
              	
                (a)

              	
                based
      on Development Materials which, upon delivery pursuant to the applicable
      delivery terms were in compliance with the Specifications and in respect
      of which the Services were performed in accordance with this
      Agreement;

              

      

    

    

    
      	
            	
              
                (b)

              

            	
              
                resulting
      from any breach of this Agreement by Novartis or its Affiliates;
      or

              

            

    

    

    
      	
            	
              
                (c)

              

            	
              
                resulting
      from Novartis’ willful misconduct or negligence in respect of the
      performance or failure to perform any of its obligations under this
      Agreement.

              

            

    

    

    
      	
              12.3

            	
              The
      indemnification obligations of Novartis and GenVec, as the case may be,
      shall apply only if:

            

    

    

    
      
        	
              	
                (a)

              	
                the
      party asserting its rights (the "Indemnitee") promptly notifies the other
      party (the "Indemnitor") in writing after Indemnitee receives notice of
      any Claim (unless such failure does not materially prejudice the
      Indemnitor);

              

      

    

    

    
      	
            	
              
                (b)

              

            	
              
                the
      Indemnitee has refrained and continues to refrain from making any
      admission of liability or any attempt to settle any such Claim without the
      Indemnitor’s consent;

              

            

    

    

    
      	
            	
              
                (c)

              

            	
              
                the
      Indemnitor is given the opportunity to manage and control the defence of
      such Claim; and

              

            

    

    

    
      	
            	
              
                (d)

              

            	
              
                the
      Indemnitee reasonably cooperates with Indemnitor, at the Indemnitor’s sole
      cost, in the defence of any such
Claim.

              

            

    

    

    
      	
              12.4

            	
              The
      Indemnitee may be represented by its own legal counsel in respect of any
      Claim, at its own expense.

            

    

    

    
      	
              12.5

            	
              The
      Indemnitor may not settle a Claim without the consent of the Indemnitee,
      which consent may not be unreasonably withheld. However, if the Indemnitee
      rejects a settlement at a specific amount, the Indemnitee shall be liable
      for all Claims in excess of that proposed settlement
    amount.

            

    

     

    * The asterisk denotes that confidential portions of this exhibit have been
omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The
confidential portions have been submitted separately to the Securities and
Exchange Commission.

     

    
      
         

      

      
        21

        
          

        

      

      
         

      

    

     

    
      
        
          
            	
                    Agreement
      for the Supply of Services Relating
      to

                    Development
      Materials

                  

          

        

      

    

     

    
      	
              12.6

            	
              Neither
      party shall be liable to indemnify the other to the extent that any Claims
      arise out of the negligence, willful misconduct, bad faith or breach of
      this Agreement by any indemnified party or its
  Affiliates.

            

    

    

    
      	
              12.7

            	
              NEITHER
      PARTY SHALL BE LIABLE TO THE OTHER FOR ANY CONSEQUENTIAL, INCIDENTAL,
      PUNITIVE OR INDIRECT DAMAGES, INCLUDING WITHOUT LIMITATION LOSS OF
      ANTICIPATED PROFITS AND INVESTMENTS, EXCEPT TO THE EXTENT SUCH DAMAGES
      WERE CAUSED BY THE GROSS NEGLIGENCE OR WILLFUL MISCONDUCT OF THAT PARTY OR
      ITS AFFILIATES.

            

    

    

    
      	
              12.8

            	
              Each
      party warrants that it has appropriate and adequate insurance to cover
      claims or damages for which it shall be liable under the terms of this
      Agreement. Upon the request of either party, the other party shall supply
      evidence of such insurance satisfactory to
  Novartis.

            

    

     

    
      	
              13.

            	
              Changes
      to and Interruptions of Work Orders

            

    

    

    
      	
              13.1

            	
              Novartis
      may request changes to any Work Order at any time by issuing a notice to
      GenVec in writing.

            

    

    

    
      	
              13.2

            	
              GenVec
      shall inform Novartis in writing immediately with regard to impact on
      costs, effects on agreed deadlines, or any other effects arising out of a
      change to a Work Order.

            

    

    

    
      	
              13.3

            	
              GenVec
      shall not implement any change to any Work Order unless an amendment to
      such Work Order has been executed by the
  parties.

            

    

     

    
      	
              14.

            	
              Confidentiality
      and Non-Use

            

    

    

    
      	
              14.1

            	
              Neither
      party shall disclose to any third party, and/or use for any purpose other
      than to perform its obligations under this Agreement, any Confidential
      Information of the other party hereto, or any of its Affiliates or
      sub-contractors, without the prior written consent of the other party.
      Notwithstanding the foregoing, neither party may disclose the other
      party’s Confidential Information to employees and consultants, including
      those if its Affiliates, who are not bound by obligations not less strict
      than those set out herein.

            

    

    

    
      	
              14.2

            	
              “Confidential
      Information” of Novartis or of GenVec, as the case may be, shall be all
      proprietary information of that party, which is not in the public domain.
      “Confidential Information” of Novartis shall include without limitation
      the Technical Information, the Novartis Data, all improvements to and
      derivatives of the Technical Information and the Novartis Data made by or
      on behalf of GenVec, and all data, results, information, inventions and
      other Intellectual Property obtained in or arising out of the Services.
      However, “Confidential Information” of Novartis or of GenVec, as the case
      may be, shall not include any information which, as shown by clear written
      evidence,:

            

    

    

    
      
        	
              	
                (a)

              	
                was
      already in the public domain at the time of receipt from the other
      party;

              

      

    

     

    * The asterisk denotes that confidential portions of this exhibit have been
omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The
confidential portions have been submitted separately to the Securities and
Exchange Commission.

     

    
      
         

      

      
        22

        
          

        

      

      
         

      

    

    
       

      
        
          
            	
                    Agreement
      for the Supply of Services Relating
      to

                    Development
      Materials

                  

          

        

      

    

     

    
      
        	
              	
                (b)

              	
                was
      known to the receiving party prior to receipt from the other
      party;

              

      

    

    

    
      	
            	
              
                (c)

              

            	
              
                has
      become generally available through no act on the part of the receiving
      party;

              

            

    

    

    
      	
            	
              
                (d)

              

            	
              
                corresponds
      to information received in good faith by the receiving party from a third
      party having a right to disclose such information;
  or

              

            

    

    

    
      	
            	
              
                (e)

              

            	
              
                was
      independently developed by the receiving
  party.

              

            

    

    

    
      	
              14.3

            	
              Notwithstanding
      any other provision of this Agreement, the parties may disclose
      Confidential Information which is required to be
  disclosed:

            

    

    

    
      
        	
              	
                (a)

              	
                to
      governmental agencies for product registration or other regulatory
      purposes; or

              

      

    

    

    
      
        	
              	
                (b)

              	
                if
      requested pursuant to an order of a competent court or administrative
      agency, provided that the party subject to such order has informed the
      disclosing party thereof in writing in order to enable the latter to seek
      a protective order or other appropriate remedy to prevent or limit such
      disclosure, and has used reasonable efforts to limit the scope of the
      disclosure and to obtain confidential treatment by the
    court.

              

      

    

    

    
      	
              14.4

            	
              The
      parties to this Agreement undertake to keep the terms and conditions of
      this Agreement in strict confidence and not to disclose any such
      information to any third parties other than to Novartis’ employees and
      consultants, including those of its Affiliates or sub-contractors, who are
      bound by obligations not less strict than those set out herein,
      except:

            

    

    

    
      
        	
              	
                (a)

              	
                as
      may be required by law (including without limitation disclosures required
      by the US Securities and Exchange Commission and its foreign
      equivalents);

              

      

    

    

    
      
        	
              	
                (b)

              	
                as
      may be necessary for obtaining or maintaining authorizations or permits in
      respect of the Services to be performed under this Agreement;
      or

              

      

    

    

    
      
        	
              	
                (c)

              	
                as
      mutually agreed by the parties in
writing.

              

      

    

    

    
      	
              14.5

            	
              The
      obligations of confidentiality and non-use contained in this Section 14
      shall survive the termination of this Agreement for
  *.

            

    

     

    * The asterisk denotes that
confidential portions of this exhibit have been omitted in reliance on Rule
24b-2 of the Securities Exchange Act of 1934. The confidential portions have
been submitted separately to the Securities and Exchange Commission.

     

    
      
         

      

      
        23

        
          

        

      

      
         

      

    

     

    
      
        
          
            	
                    Agreement
      for the Supply of Services Relating
      to

                    Development
      Materials

                  

          

        

      

    

     

    
      	
              15.

            	
              Conflict
      of Interest

            

    

    

    
      GenVec
warrants that it is presently, and shall remain, for the term of this Agreement
and any extension thereof, free from any commitments that would create a
conflict of interest impeding the completion of GenVec’s obligations hereunder.
As an independent contractor, GenVec may perform services for third parties,
outside of the time devoted to Novartis under this Agreement, except where there
is a direct conflict of interest with the Services.

    

     

    
      	
              16.

            	
              Sub-Contracting

            

    

    

    GenVec
shall not sub-contract any of the Services under this Agreement without prior
written consent from Novartis. Notwithstanding any such approval, GenVec may
subcontract the Services to Sigma-Aldrich, Inc. and its Affiliates (“SAFC”) and
SriSai Biopharmaceutical Services, Inc. and its Affiliates (SrISai), but shall
be responsible for the performance of the Services by SAFC, SriSai and its other
sub-contractors and shall not be relieved of its obligations under this
Agreement. GenVec shall be responsible for paying its sub-contractors. GenVec
shall have written agreements with its sub-contractors, binding its
sub-contractors used in connection with this Agreement to obligations which are
no less strict than those set out herein.

    

    
      	
              17.

            	
              Non-Assignment

            

    

    

    Neither
this Agreement nor any of the rights or obligations hereunder may be assigned by
a party without the prior written consent of the other party, except (a)
Novartis may assign this Agreement, in whole or in part, to an Affiliate of
Novartis; and (b) each Party may assign this Agreement, in whole, to a third
party that acquires, by merger, sale of assets or otherwise, all or
substantially all of the business of the assigning party to which the subject
matter of this Agreement relates.  Any assignment not in accordance
with the foregoing shall be void.  This Agreement shall be binding
upon, and shall inure to the benefit of, all permitted successors and
assigns.

    

    
      	
              18.

            	
              Force
      Majeure

            

    

    

    The
parties hereto shall not be liable for non-fulfillment of their respective
obligations hereunder, if such non-fulfillment is due events beyond the
reasonable control of the party affected (hereinafter “Force Majeure”), such as
to strikes, riots, war, invasion, acts of God, fire, explosion, floods, delay of
carrier, acts of government agencies, judicial action, labor disturbance . The
party affected by Force Majeure shall promptly provide the other party with full
particulars thereof (including its best estimate of the likely extent and
duration of the interference with its activities), and will use its reasonable
best endeavors to overcome the difficulties created thereby and to resume
performance of its obligations as soon as possible. If a condition constituting
Force Majeure exists for more than ninety (90) consecutive days, the parties
shall meet to negotiate a mutually satisfactory solution to the problem, if
practicable, including the use of a third party to fulfill the obligations
hereunder of the party invoking Force Majeure, at the expense of the party
invoking Force Majeure.

     

    * The asterisk denotes that confidential portions of this exhibit have been
omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The
confidential portions have been submitted separately to the Securities and
Exchange Commission.

     

    
      
         

      

      
        24

        
          

        

      

      
         

      

    

    
       

      
        
          
            	
                    Agreement
      for the Supply of Services Relating
      to

                    Development
      Materials

                  

          

        

      

    

     

    
      	
              19.

            	
              Governing
      Law and Venue

            

    

     

    
      This
Agreement shall be governed by and construed in accordance with the laws of
Switzerland; provided, that matters of intellectual property law concerning the
existence, validity, ownership, infringement or enforcement of intellectual
property shall be determined in accordance with the national intellectual
property laws relevant to the intellectual property in question.

    

     

    
      Any
unresolved disputes between the Parties relating to, arising out of or in any
way connected with this Agreement or any term or condition hereof, or the
performance by either Party of its obligations hereunder, whether before or
after termination of this Agreement, shall be resolved by final and binding
arbitration.  Whenever a Party shall decide to institute arbitration
proceedings, it shall give written notice to that effect to the other
Party.  Arbitration shall be held in New York, New York, according to
the commercial rules of the International Chamber of Commerce
(“ICC”).  The arbitration will be conducted by a panel of three
arbitrators appointed in accordance with ICC rules; provided that each Party
shall, within thirty (30) days after the institution of the arbitration
proceedings, appoint an arbitrator, and such arbitrators shall together, within
thirty (30) days, select a third arbitrator as the chairman of the arbitration
panel.  Each arbitrator shall have significant experience in the
bio-pharmaceutical business.  If the two initial arbitrators are
unable to select a third arbitrator within such thirty (30) day period, the
third arbitrator shall be appointed in accordance with ICC
rules.  Discovery shall be subject to all applicable privileges and
other immunities under the U.S. Federal Rules of Civil Procedure and shall be
limited to: *.  The Parties shall request that the arbitrators render
their opinion within thirty (30) days of the final arbitration
hearing.  No arbitrator (nor the panel of arbitrators) shall have the
power to award punitive damages under this Agreement and such award is expressly
prohibited.  Decisions of the panel of arbitrators shall be final and
binding on the Parties.  Judgment on the award so rendered may be
entered in any court of competent jurisdiction.  The losing Party to
the arbitration (if any) as determined by the arbitrators shall pay the costs of
the arbitration.

    

    

    
      	
              20.

            	
              Relationship
      between Parties/Employees

            

    

    

    
      	
              20.1

            	
              For
      the purposes of this Agreement, each party shall be an independent
      contractor and not an agent or employee of the other party. Neither party
      shall have authority or power to make any statements, representations or
      commitments of any kind, or to take any action which is binding on the
      other party, except as may be explicitly authorized by the other party in
      writing.

            

    

    

    
      
        	
                20.2

              	
                GenVec
      retains the sole right to hire, discipline, evaluate and terminate the
      employment of its own employees and to set their hours, wages and terms
      and conditions of employment in accordance with law and GenVec’s
      obligations herein. GenVec’s employees who are involved in performing the
      Services shall be under its exclusive authority, and GenVec shall be
      responsible for their activities and actions during the performances of
      the Services.

              

      

    

     

    * The asterisk denotes that
confidential portions of this exhibit have been omitted in reliance on Rule
24b-2 of the Securities Exchange Act of 1934. The confidential portions have
been submitted separately to the Securities and Exchange Commission.

     

    
      
         

      

      
        25

        
          

        

      

      
         

      

    

    Agreement
for the Supply of Services Relating to

    
       Development
Materials 

        
          

        

      

    

     

    
      	
              20.3

            	
              All
      income, employment and other similar taxes required to be withheld and/or
      paid with respect to any Services provided hereunder will be timely paid
      by GenVec directly to the appropriate governmental
  agency.

            

    

    

    
      	
              20.4

            	
              The
      employees, representatives and collaborators of GenVec are not entitled to
      and will not receive from Novartis in connection with the Services, any
      benefits normally provided by Novartis to its employees. The GenVec agrees
      to defend, indemnify and hold Novartis harmless against any claim that
      Novartis is jointly or severally liable or obligated to GenVec’s
      employees, agents, employees’ representatives, a benefit plan or any
      governmental fund or entity on the basis of a statute, regulation or
      common law duty relating to
employment.

            

    

    

    
      
        	
                20.5

              	
                GenVec
      bears the sole responsibility for compensation (including overtime to
      hourly employees, if applicable) of its
  employees.

              

      

    

    

    
      	
              20.6

            	
              GenVec
      shall assign employees with an appropriate level of expertise and
      experience to the performance of the Services. GenVec shall ensure that
      its employees comply with all applicable laws, regulations, regulatory
      requirements (including without limitation those set forth in the
      authorisations and permits referred to in Section
  4.1.)

            

    

    

    
      
        	
                21.

              	
                Notices

              

      

    

    

    
      	
              21.1

            	
              Any
      notices, consents or approvals which either party may be required or shall
      desire to give under this Agreement shall be deemed to be duly given when
      in writing and delivered personally, mailed by registered mail or courier
      service, or sent by facsimile (confirmed by registered mail or courier
      service) to the party to whom notice is to be given, at the address
      specified below or such other address or addresses of which such party
      shall have given notice not less than seven (7) days before the notice is
      dispatched. All such notices and communications shall be deemed to have
      been received, in the case of notice by facsimile or by delivery, when
      received or if received after 5:00 pm (local time of the receiver) or on a
      day other than a business day, on the next following business day, and in
      the case of notice mailed as aforesaid, on the fifth (5th)
      business day following the date on which such notice is mailed provided
      there is no disruption of postal services. In the event of interruption of
      one or more of the forms of communication listed above for any reason, the
      parties shall use a form of communication which is not so interrupted with
      the intent that the form of communication used will give the addressee
      timely notice of the communication.

            

    

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
        26

        
          

        

      

      
         

      

    

    
       

       Agreement
for the Supply of Services Relating to

       Development
Materials 

        
          

        

      

    

     

    Notices
shall be given to the following address for each party:

    

    If to
GenVec:

    65 West
Watkins Mill Road

    Gaithersburg,
MD 20878

    USA

    Attention:  President

    Fax:
(240) 632-0735

     

    If to
Novartis in relation to this Agreement in general:

    

    Novartis
Pharma AG

    Postfach

    4002
Basel

    Switzerland

    Attention:
Global Head Technical R&D

    

    With a
copy to

    Novartis
Pharma AG

    Postfach

    4002
Basel

    Switzerland

    Attention:
General Counsel

    

    If to
Novartis in relation to any particular Work Order:

    

    To the
Novartis Affiliate which issued the Work Order, to the address specified on the
Work Order, to the attention of the Head Technical R&D , with a copy to the
General Counsel at the same address.

    

    
      	
              22

            	
              No
      License

            

    

    

    
      	
               
      

            	
              No
      license or right is granted by implication or otherwise with respect to
      any know-how, patent application or patent owned by Novartis except as and
      if specifically set forth herein.

            

    

    

    
      	
              23

            	
              Amendments

            

    

    

    
      	
               
      

            	
              Any
      amendment to the terms of this Agreement or any Work Order shall be valid
      only if the change is made in writing and is signed by GenVec and
      Novartis.

            

    

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
        27

        
          

        

      

      
         

      

    

    
       

       Agreement
for the Supply of Services Relating to

       Development
Materials 

        
          

        

      

    

     

    
      	
              24

            	
              Publicity
      and Press Releases

            

    

    

    
      	
              24.1

            	
              Subject
      to the provisions of Section 14.4(c), neither party will use, nor
      authorize others to use, the name, symbols, or marks of the other party in
      any advertising or publicity material or make any form of representation
      or statement with regard to the Services which would constitute an express
      or implied endorsement by the other party of any commercial product or
      service without that other party’s prior written
  approval.

            

    

    

    
      	
              24.2

            	
              Neither
      party shall make any press release concerning this Agreement or the
      subject-matter hereof without the prior written consent of the other
      party.

            

    

    

    
      	
              25

            	
              Debarment

            

    

    

    
      	
               
      

            	
              GenVec
      certifies that none of it, nor any of its employees, agents or
      subcontractors (including their respective employees and agents), have
      ever been, are currently, or are the subject of a proceeding that would
      reasonably be expected to lead to it or such employees or agents becoming,
      as applicable, a Debarred Entity or Debarred Individual, an Excluded
      Entity or Excluded Individual or a Convicted Entity or Convicted
      Individual.  GenVec certifies that if, during the term of this
      Agreement, it, or any of its employees, agents or subcontractors, become
      or are the subject of a proceeding that would reasonably be expected to
      lead to a person becoming, as applicable, a Debarred Entity or Debarred
      Individual, an Excluded Entity or Excluded Individual or a Convicted
      Entity or Convicted Individual, GenVec shall immediately notify Novartis
      in writing.  For purposes of this provision, the following
      definitions shall apply:

            

    

    
      	
              (a)

            	
              A
      “Debarred Individual” is an individual who has been debarred by the FDA
      pursuant to 21 U.S.C. §335a (a) or (b) from providing services in any
      capacity to a person that has an approved or pending drug or biological
      product application.

            

    

    
      	
              (b)

            	
              A
      “Debarred Entity” is a corporation, partnership or association that has
      been debarred by the FDA pursuant to 21 U.S.C. §335a (a) or (b) from
      submitting or assisting in the submission of any abbreviated drug
      application.

            

    

    
      	
              (c)

            	
              An
      “Excluded Individual” or “Excluded Entity” is (i) an individual or entity,
      as applicable, who has been excluded, debarred, suspended or is otherwise
      ineligible to participate in Federal health care programs (as defined in
      43 U.S.C. §1320a-7b(f)(1)), such as Medicare or Medicaid, by the Office of
      the Inspector General (OIG/HHS) of the U.S. Department of Health and Human
      Services, or (ii) is an individual or entity, as applicable, who has been
      excluded, debarred, suspended or is otherwise ineligible to participate in
      federal procurement and non-procurement programs, including those produced
      by the U.S. General Services Administration
  (GSA).

            

    

    
      	
              (d)

            	
              A
      “Convicted Individual” or “Convicted Entity” is an individual or entity,
      as applicable, who has been convicted of a criminal offense described in
      21 U.S.C. §335a (a) or 42 U.S.C. §1320a - 7(a), but has not yet been
      excluded, debarred, suspended or otherwise declared ineligible as
      described in clauses (a), (b) or (c) of this
  provision.

            

    

    

    
      	
              26

            	
              Entire
      Agreement

            

    

    

    
      	
               
      

            	
              The
      Collaboration Agreement and this Agreement, including the Annexes and any
      Work Orders issued hereunder, represents the entire understanding of the
      parties with respect to the subject matter hereof, and supersedes all
      prior and contemporaneous agreements or understandings, oral or written,
      with respect thereto.  In case of discrepancies between the
      terms of this Agreement and a Work Order, the terms of the Agreement shall
      prevail.

            

    

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
        28

        
          

        

      

      
         

      

    

    
       

       Agreement
for the Supply of Services Relating to

       Development
Materials 

        
          

        

      

    

    

    27             Severability

    

    If any
term or provision of this Agreement is held to be invalid or unenforceable, in
whole or in part, under any applicable enactment or rule of law, such illegality
or unenforceability shall not affect the remainder of this Agreement, and the
parties shall in good faith attempt to substitute a valid and enforceable
provision which achieves to the nearest extent possible the same effect as would
have been achieved by the invalid or unenforceable provision.

    

    28             Waiver

    

    No waiver
of any term, provision or condition of this Agreement, whether by conduct or
otherwise in any one or more instances, shall be deemed to be or construed as a
further or continuing waiver of any such term, provision or condition, or of any
other term, provision or condition of this Agreement.

    

    29             *

    

    30             Corporate
Citizenship

    

     Novartis
gives preference to third parties who share Novartis' societal and environmental
values, as set forth in the Novartis Policy on Corporate Citizenship, Guideline
#5, Third Party Code .

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
        29

        
          

        

      

      
         

      

    

    
       

       Agreement
for the Supply of Services Relating to

       Development
Materials 

        
          

        

      

    

    

    Annex
D : Quality Assurance Agreement

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
        30

        
          

        

      

      
         

      

    

    
       

      QUALITY
AGREEMENT ON MANUFACTURING, (PACKAGING) AND TESTING 

        
          

        

      

    

    

    
      
        
          
            
              
                
                  
                    
                      
                        
                          	
                                  Between

                                
	 
	
                                  NOVARTIS
      PHARMA AG

                                     

                                  including
      Process Science and Production

                                
	 
	
                                  Lichtstrasse
      35,

                                  4002
      CH-Basel, Switzerland

                                
	 
	
                                  as
      contract giver, subsequently named NOVARTIS

                                
	 
	
                                  And

                                
	 
	
                                  GenVec

                                
	 
	
                                  65
      West Watkins Mill Road Gaithersburg MD 20878 USA

                                
	 
	
                                  as
      contract acceptor, subsequently named ACCEPTOR

                                
	 
      
	
                                  First
      edition

                                

                        

                      

                    

                  

                

              

            

          

        

      

    

    
       

      
        
          
            
              
                
                  
                    	
                            NOVARTIS   initials:

                          	 	
                            ACCEPTOR   initials:
      

                          
	
                            QAA Novartis Genvec
      - Core Document   31/6

                          	
                             

                          	 
      	
                            Version
      1.0

                          

                  

                

              

            

          

        

        

        * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

      

    

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    
       

      QUALITY
AGREEMENT ON MANUFACTURING, (PACKAGING) AND TESTING 

        
          

        

      

    

     

    
      TABLE
OF CONTENTS

    

     

    
      
        
          
            
              
                	
                        PREAMBLE

                      	
                        35

                      
	 	 	 
	
                        1.

                      	
                        SCOPE
      of the Quality agreement

                      	
                        35

                      
	 
      	 
      	 
      
	
                        2.

                      	
                        General
      Provisions (Quality assurance)

                      	
                        36

                      
	
                        *

                      	 
      	 
      
	
                        3.

                      	
                        Development

                      	
                        44

                      
	 
      	 
      	 
      
	
                        4.

                      	
                        RAW
      Material

                      	
                        44

                      
	
                        *

                      	 
      	 
      
	
                        5.

                      	
                        Manufacturing
      of Products

                      	
                        46

                      
	
                        *

                      	 
      	 
      
	
                        6.

                      	
                        Testing
      of Products

                      	
                        50

                      
	
                        *

                      	 
      	 
      
	
                        *

                      	 
      	 
      
	
                        7.

                      	
                        ARCHIVING
      OF Samples and Documentation

                      	
                        52

                      
	 
      	 
      	 
      
	
                        8.

                      	
                        Release
      of Products

                      	
                        53

                      
	
                        *

                      	 
      	 
      
	
                        9.

                      	
                        Product
      Security

                      	
                        54

                      
	
                        *

                      	 
      	 
      
	
                        10.

                      	
                        Stability
      testing and Product surveillance

                      	
                        55

                      
	
                        *

                      	 
      	 
      
	
                        11.

                      	
                        Terms
      and Expiration

                      	
                        55

                      
	 
      	 
      	 
      
	
                        12.

                      	
                        DEFINITIONS

                      	
                        56

                      
	 
      	 
      	 
      
	
                        13.

                      	
                        Signatures

                      	
                        57

                      

              

            

          

        

      

    

    
       

    

    
      
        
          	
                  NOVARTIS   initials:

                	 
      	
                  ACCEPTOR   initials:
      

                
	
                  QAA Novartis Genvec
      - Core Document   32/6

                	  	  
      	
                  Version 1.0
      

                

        

      

    

    

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    
       

      QUALITY
AGREEMENT ON MANUFACTURING, (PACKAGING) AND TESTING 

        
          

        

      

    

     

     TABLE
OF ENCLOSURES

     

    
      
        	
                ENCLOSURE
      A: LIST OF QA/QC LIAISONS

              

      

    

    
      
        ENCLOSURE
BX:
PRODUCT MANUFACTURING AND TESTING
DOCUMENTS, BILL OF MATERIALS, AND STABILITY
PROGRAM

      

    

    
      
        	
                ENCLOSURE
      C: TABLE OF
      RESPONSIBILITIES

              

      

    

    
      
        	
                ENCLOSURE
      D : LIST OF APPROVED
      SUBCONTRACTORS

              

      

    

    
      
        	
                ENCLOSURE
      E: HISTORY OF
      CHANGES

              

      

    

     

    
      
        
          
            	
                    NOVARTIS   initials:

                  	 
      	
                    ACCEPTOR   initials:
      

                  
	
                    QAA
      Novartis Genvec - Core Document   33/6

                  	
                     
      

                  	 
      	
                    Version
      1.0 

                  

          

        

      

      

      * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    
       

      QUALITY
AGREEMENT ON MANUFACTURING, (PACKAGING) AND TESTING 

        
          

        

      

       

    

    PREAMBLE

     

    NOVARTIS
is a leading company engaged in the manufacture, marketing and sales of
pharmaceutical products. It operates under one common Quality Management System
incorporating GMP guidelines and major laws and regulations. NOVARTIS desires to
entrust ACCEPTOR * ACCEPTOR is interested in performing such activities for
NOVARTIS.

     

    If
available, ACCEPTOR and/or its contractors shall provide a copy of the newest
Health authorities GMP certificates (manufacturing licence) valid for each site
concerned by the contracted activities (including biosafety certificates as
appropriate).

     

     ACCEPTOR
shall inform NOVARTIS of any change / update in the cGMP and biosafety status as
certified by the Health Authority and shall provide relevant updated
documentation, as long as this Quality Agreement remains valid.

     

    ACCEPTOR
and NOVARTIS are to define their roles and responsibilities according to the
intentions of the EU/PIC GMP Guidelines. In addition to the requirements below
ACCEPTOR shall follow the guidelines of the ICH, the US Code of Federal
Regulations and
the corresponding national guidelines prevailing at the time of the
manufacture.

     

    SCOPE
of the Quality agreement

     

    This Quality
Agreement forms an integrated part of the Development and Manufacturing
Agreement. It defines the contacts for all technical and quality matters
(see Enclosure A). It covers
* Enclosures are to be approved by QA responsibles only and can be completed and
approved for specific items independently of the approval of the core of this
Quality Agreement.

     

    *

     

    It defines
the manufacturing, the testing documents and stability program (see Enclosure B).
The roles and responsibilities of both parties are assigned in Enclosure C. This
Quality Agreement establishes the reliance of NOVARTIS on the decisions made by
ACCEPTOR or other involved contractors (see  Enclosure D). Changes
to this Quality Agreement will be listed in Enclosure
E. The
enclosures are signed by the quality responsible persons
only.

     

    
      
        
          
            
              	
                      NOVARTIS   initials:

                    	  
      	
                       ACCEPTOR   initials:
      

                    
	
                      QAA Novartis Genvec
      - Core Document   34/6

                    	
                       
      

                    	 
      	
                      Version 1.0
      

                    

            

          

        

        

        * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

      

    

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    
       

      QUALITY
AGREEMENT ON MANUFACTURING, (PACKAGING) AND TESTING 

        
          

        

      

       

    

    In the
event of a conflict between the Quality Agreement and the Development and
Manufacturing Agreement then the Development and Manufacturing Agreement shall
govern except to the extent such provisions are violating the GMP
regulations.

     

    General
Provisions (Quality assurance)

     

    *

     

    Development

     

    *

     

    RAW
Material

     

    *

     

    
      Manufacturing
of Products

    

     

    *

     

    *

     

    Testing
of Products

     

    *

     

    ARCHIVING
OF Samples and Documentation

     

    *

     

    
      
        
          
            
              
                	
                        NOVARTIS   initials:

                      	 
      	
                        ACCEPTOR   initials:
      

                      
	
                        QAA
      Novartis Genvec - Core Document   35/6

                      	
                         

                      	 
      	
                        Version
      1.0

                      

              

            

          

          

          * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

        

      

       

    

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    
       

      QUALITY
AGREEMENT ON MANUFACTURING, (PACKAGING) AND TESTING 

        
          

        

      

       

    

    Release
of Products

     

    
      
        	
                ·

              	
                *

              

      

    

     

    Product
Security

     

    
      	
              ·

            	
              *

            

    

     

    Stability
testing and Product surveillance

     

    *

     

    Terms
and Expiration

    *

     

    DEFINITIONS*

     

    Signatures

     

    
      
        
          
            
              
                
                  
                    
                      
                        
                          	
                                  NOVARTIS

                                	 
      	
                                  ACCEPTOR

                                
	 	 	 
	 	 	 
	
                                  Name

                                  Function

                                	 	
                                  Name

                                  Function

                                
	 	 	 
	 	 	 
	
                                  Name

                                  Function

                                	 
      	
                                  Name

                                  Function

                                

                        

                      

                    

                  

                

              

            

          

        

      

    

    
       

    

    
      
        
          	
                  NOVARTIS   initials:

                	 
      	
                  ACCEPTOR   Initials:

                
	
                  QAA
      Novartis Genvec - Core Document   36/6

                	
                   

                	 
      	
                  Version
      1.0

                

        

      

    

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    
       

      QUALITY
AGREEMENT ON MANUFACTURING, (PACKAGING) AND TESTING 

        
          

        

      

       

    

    ENCLOSURE
A: List of QA/QC Liaisons

     

    
      
        
          
            
              
                
                  
                    
                      
                        
                          	
                                  NOVARTIS

                                
	
                                  Name

                                	 	
                                  Function

                                	 	
                                  Telephone

                                	 	
                                  e-mail

                                
	
                                  L.
      Bessueille

                                	 	
                                  Global
      Head Quality,  NBx QA

                                	 	
                                  +41616961920

                                	 	
                                  lucile.bessueille@novartis.com

                                
	
                                  N.
      Rellier

                                	 	
                                  Head
      External Quality, NBx QA

                                	 	
                                  +41616965072

                                	 	
                                  nadege.rellier@novartis.com

                                
	
                                  U.
      Knof

                                	 	
                                  Head
      NBx QA

                                	 	
                                  +416169
      63 443

                                	 	
                                  ulrich.knof@novartis.com

                                
	
                                  P.
      Meissner

                                	 	
                                  Technical
      Project Leader

                                	 	
                                  +41613246776

                                	 	
                                  petra.meissner@novartis.com

                                
	
                                  K.
      Foerstner

                                	 	
                                  DSM
      Franchise Head

                                	 	
                                  +41794664356

                                	 	
                                  katrin.foerstner@novartis.com

                                

                        

                      

                    

                  

                

              

            

          

        

      

    

    

    
      
        
          
            	
                    ACCEPTOR

                  

          

        

      

    

    

    
      
        
          
            
              
                
                  
                    
                      
                        
                          
                            
                              
                                	
                                        Name

                                      	 	
                                        Function

                                      	 	
                                        Telephone

                                      	 	
                                        e-mail

                                      
	
                                        Mike
      Sowers

                                      	 	
                                        Director,
      Quality Assurance

                                      	 	
                                        301-944-1173

                                      	 	
                                        msowers@genvec.com

                                      
	
                                        Clem
      Purcell

                                      	 	
                                        Director,
      Quality Control

                                      	 	
                                        240-632-5552

                                      	 	
                                        cpurcell@genvec.com

                                      
	
                                        Perry
      Newton

                                      	 	
                                        Director,
      Manufacturing Sciences

                                      	 	
                                        240-632-5560

                                      	 	
                                        pnewton@genvec.com

                                      
	
                                        Vicki
      Haque

                                      	 	
                                        Director,
      Project Management

                                      	 	
                                        301-944-1170

                                      	 	
                                        vhaque@genvec.com

                                      
	
                                        Tammy
      McCracken

                                      	 	
                                        Associate
      Director, Regulatory Affairs

                                      	 	
                                        240-848-1046

                                      	 	
                                        tmccracken@genvec.com

                                      
	
                                        Bryan
      Butman,

                                      	 	
                                        Sr.
      Vice President, Operations

                                      	 	
                                        240-632-5554

                                      	 	
                                        bbutman@genvec.com

                                      

                              

                            

                          

                        

                      

                    

                  

                

              

            

          

        

      

    

     

    
      
        
          
            
              
                
                  
                    
                      
                        	
                                NOVARTIS   initials:

                              	 
      	
                                ACCEPTOR   Initials:
      

                              
	
                                This
      document contains proprietary information and may not be divulged without
      prior written approval of Contract Parties

                              
	 	 	 	 
	
                                QAA
      Novartis Genvec - Enclosure
      B       1/2

                              	
                                 

                              	 
      	
                                Version
      1.0

                              

                      

                    

                  

                

              

            

          

        

         

        * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

        

          
            
               

            

            
               

              
                

              

            

            
               

            

          

        

      

    

    
       

      QUALITY
AGREEMENT ON MANUFACTURING, (PACKAGING) AND TESTING 

        
          

        

      

    

    
      
        	
                CONTRACTOR
      (CMO: SAFC Pharma)

              

      

    

     

    
      
        
          
            
              	
                      Name

                    	 
      	
                      Function

                    	 
      	
                      Telephone

                    	 
      	
                      e-mail

                    
	
                      Jennifer
      Collins

                    	 
      	
                      Sr.
      Manager, Quality Assurance

                    	 
      	
                      760-710-6109

                    	 
      	
                      Jennifer.Collins@sial.com

                    

            

          

        

      

    

    

    
      
        
          
            	
                    NOVARTIS

                  	 
      	
                    ACCEPTOR

                  
	 	 	 
	 
      	 
      	 
      
	
                    Name

                    Function

                  	 
      	
                    Name

                    Function

                  

          

        

      

    

    

    
      
        
          
            
              
                	
                        NOVARTIS   initials:

                      	 
      	
                        ACCEPTOR   initials:

                      
	
                        This
      document contains proprietary information and may not be divulged without
      prior written approval of Contract Parties

                      
	 
      	 
      	 
      	 
      
	
                        QAA
      Novartis Genvec - Enclosure
      B       2/2

                      	
                         

                      	 
      	
                        Version1.0

                      

              

            

          

        

      

    

       

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    
       

      QUALITY
AGREEMENT ON MANUFACTURING, (PACKAGING) AND TESTING 

        
          

        

      

    

     

    ENCLOSURE
B1: Product Manufacturing and Testing Documents, Bill of Materials, and
Stability Program for MCB*

     

    
      
        
          
            	
                    NOVARTIS

                  	 
      	
                    ACCEPTOR

                  
	 	 	 
	 
      	 
      	 
      
	
                    Name

                    Function

                  	 
      	
                    Name

                    Function

                  

          

        

      

    

    
       

    

    
      
        
          	
                  NOVARTIS   initials:

                	 
      	
                  ACCEPTOR   initials:

                
	
                  This
      document contains proprietary information and may not be divulged without
      prior written approval of Contract Parties

                
	 
      
	
                  QAA
      Novartis Genvec -
      Enclosure C       1/2

                	
                   

                	 
      	
                  Version1.0

                

        

      

    

       

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    
       

      QUALITY
AGREEMENT ON MANUFACTURING, (PACKAGING) AND TESTING 

        
          

        

      

    

     

    ENCLOSURE
B3: List of Products To Be Manufactured Within the Scope of QAA*

     

    
      
        
          
            	
                    NOVARTIS

                  	 
      	
                    ACCEPTOR

                  
	 
      	 
      	 
      
	 	 	 
	
                    Name

                    Function

                  	 
      	
                    Name

                    Function

                  

          

        

      

    

     

    
      
        
          
            	
                    NOVARTIS   initials:

                  	 
      	
                    ACCEPTOR   initials:

                  
	
                    This
      document contains proprietary information and may not be divulged without
      prior written approval of Contract Parties

                  
	 
      
	
                    QAA
      Novartis Genvec - Enclosure
      C       2/2

                  	
                     

                  	 
      	
                    Version1.0

                  

          

        

      

         

    

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    
       

      QUALITY
AGREEMENT ON MANUFACTURING, (PACKAGING) AND TESTING 

        
          

        

      

    

     

    ENCLOSURE
C: Table of Responsibilities

     

    A           =           ACCEPTOR
CMOs

     

    B           =           NOVARTIS

     

    C           =           ACCEPTOR

     

    D           =           Other
Party (e.g. Contract Testing Organization [CTO], Contract Manufacturing
Organization [CMO], Contract Storage Facility, DSM – Drug Supply
Management)*

     

    
      
        	
                NOVARTIS

              	 
      	
                ACCEPTOR

              
	 	 	 
	 
      	 
      	 
      
	
                Name

                Function

              	 
      	
                Name

                Function

              

      

    

    
       

      
        
          
            
              	
                      NOVARTIS   initials:

                    	 
      	
                      ACCEPTOR   initials:

                    
	
                      This
      document contains proprietary information and may not be divulged without
      prior written approval of Contract Parties

                    
	 
      
	
                      QAA
      Novartis Genvec - Enclosure
      D       1/2

                    	
                       

                    	  
      	
                      Version1.0

                    

            

          

        

           

      

      * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    
       

      QUALITY
AGREEMENT ON MANUFACTURING(, PACKAGING) AND TESTING 

        
          

        

      

       

    

    ENCLOSURE
D: List of Approved Sub-Contractors

     

    
      
        
          
            
              
                
                  
                    
                      
                        
                          
                            
                              
                                
                                  
                                    
                                      	
                                              Name

                                            	 	
                                              Service

                                            	 	 
      	 	
                                              Date

                                            
	
                                              SAFC
      Pharma

                                            	 	
                                              D,
      E, B

                                            	 	
                                              Last
      Audit

                                            	 	
                                              06
      Mar 2008

                                            
	
                                              Carlsbad,
      CA

                                            	 	 
      	 	
                                              Quality
      agreement

                                            	 	
                                              24
      Mar 2008

                                            
	 
      
	
                                              Name

                                            	 	
                                              Service

                                            	 	 
      	 	
                                              Date

                                            
	
                                              SriSai
      Biopharmaceutical Services

                                            	 	
                                              F
      (storage)

                                            	 	
                                              Last
      Audit

                                            	 	
                                              08
      May 2008

                                            
	
                                              Frederick,
      MD

                                            	 	 
      	 	
                                              Quality
      agreement

                                            	 	
                                              27
      May 2010

                                            
	 
      
	
                                              Name

                                            	 	
                                              Service

                                            	 	 
      	 	
                                              Date

                                            
	
                                              AltheaDx

                                            	 	
                                              B,
      C

                                            	 	
                                              Last
      Audit

                                            	 	
                                              14
      Aug 2009

                                            
	
                                              San
      Diego, CA

                                            	 	 
      	 	
                                              Quality
      agreement

                                            	 	
                                              19
      Jan 2010

                                            
	 
      	 	 
      	 	 
      	 	 
      
	
                                              Name

                                            	 	
                                              Service

                                            	 	 
      	 	
                                              Date

                                            
	
                                              Wuxi
      AppTec

                                            	 	
                                              B

                                            	 	
                                              Last
      Audit

                                            	 	
                                              05
      Aug 2009

                                            
	
                                              Philadelphia,
      PA

                                            	 	 
      	 	
                                              Quality
      agreement

                                            	 	
                                              24
      Jul
2008

                                            

                                    

                                  

                                

                              

                            

                          

                        

                      

                    

                  

                

              

            

          

        

      

    

     

    
      
        
          	
                  NOVARTIS   initials:

                	 	
                  ACCEPTOR   initials:

                
	
                  This
      document contains proprietary information and may not be divulged without
      prior written approval of Contract Parties

                
	 
      
	
                  QAA Novartis Genvec
      - Enclosure E       1/2

                	
                   

                	 
      	
                  Version1.0

                

        

      

    

        

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

     

    
      
         

      

      
        1

        
          

        

      

      
         

      

    

    
       

      QUALITY
AGREEMENT ON MANUFACTURING(, PACKAGING) AND TESTING 

        
          

        

      

       

      
        
          
            
              
                
                  
                    
                      
                        
                          
                            
                              
                                
                                  
                                    	
                                            Name

                                          	 	
                                            Service

                                          	 	 
      	 	
                                            Date

                                          
	
                                            Wuxi
      AppTec

                                          	 	
                                            B

                                          	 	
                                            Last
      Audit

                                          	 	
                                            07
      Jan 2008

                                          
	
                                            St.
      Paul, MN

                                          	 	 
      	 	
                                            Quality
      agreement

                                          	 	
                                            24
      Jul 2008

                                          
	 
      	 	 
      	 	 
      	 	 
      
	
                                            Name

                                          	 	
                                            Service

                                          	 	 
      	 	
                                            Date

                                          
	
                                            Nelson
      Laboratories

                                          	 	
                                            B

                                          	 	
                                            Last
      Audit

                                          	 	
                                            23
      Mar 2009

                                          
	
                                            Salt
      Lake City, UT

                                          	 	 
      	 	
                                            Quality
      agreement

                                          	 	
                                            07
      Mar 2007

                                          
	 
      	 	 
      	 	 
      	 	 
      
	
                                            Name

                                          	 	
                                            Service

                                          	 	 
      	 	
                                            Date

                                          
	
                                            BioReliance

                                          	 	
                                            B

                                          	 	
                                            Last
      Audit

                                          	 	
                                            12
      Mar 2008

                                          
	
                                            Rockville,
      MD

                                          	 	 
      	 	
                                            Quality
      agreement

                                          	 	
                                            29
      Jan
2007

                                          

                                  

                                

                              

                            

                          

                        

                      

                    

                  

                

              

            

          

        

      

    

     

    
      

    

    
      

    

     

    
      
        	
                A

              	
                =
      Material supplier (optional)

              
	
                B

              	
                =
      Performs tests relevant for release

              
	
                C

              	
                =
      Performs tests not relevant for release

              
	
                D

              	
                =
      Performs or is involved in manufacturing

              
	
                E

              	
                =
      Performs or is involved in packaging

              
	
                F

              	
                =
      Provides other services

              

      

    

     

    
      
        
          
            	
                    NOVARTIS

                  	 
      	
                    ACCEPTOR

                  
	 
      	 
      	 
      
	 	 	 
	
                    Name

                    Function

                  	 
      	
                    Name

                    Function

                  

          

        

      

    

    
       

      
        
          
            	
                    NOVARTIS   initials:

                  	  
      	
                    ACCEPTOR   initials:

                  
	
                    This
      document contains proprietary information and may not be divulged without
      prior written approval of Contract Parties

                  
	 
      
	
                    QAA
      Novartis Genvec - Enclosure
      D       2/2

                  	
                     

                  	 
      	
                    Version1.0

                  

          

        

      

          

      * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    QUALITY
AGREEMENT ON MANUFACTURING(, PACKAGING) AND TESTING 

      
        

      

    

     

    ENCLOSURE
E: History of Changes

     

    
      
        
          
            
              	
                      Document
      Part

                    	 
      	
                      Version

                    	 
      	
                      Date

                    	 
      	
                      Reason
      for change

                    
	
                      Core
      Part

                    	 
      	
                      1.0

                    	 
      	
                      {dd.mm.yyyy}

                    	 
      	
                      new

                    
	
                      Enclosure
      A

                    	 
      	
                      1.0

                    	 
      	
                      {dd.mm.yyyy}

                    	 
      	
                      new

                    
	
                      Enclosure
      B

                    	 
      	
                      1.0

                    	 
      	
                      {dd.mm.yyyy}

                    	 
      	
                      new

                    
	
                      Enclosure
      C

                    	 
      	
                      1.0

                    	 
      	
                      {dd.mm.yyyy}

                    	 
      	
                      new

                    
	
                      Enclosure
      D

                    	 
      	
                      1.0

                    	 
      	
                      {dd.mm.yyyy}

                    	 
      	
                      new

                    
	
                      Enclosure
      E

                    	 
      	
                      1.0

                    	 
      	
                      {dd.mm.yyyy}

                    	 
      	
                      new

                    

            

          

        

      

    

     

    
      
        
          
            	
                    NOVARTIS
      }

                  	 
      	
                    ACCEPTOR

                  
	 
      	 
      	 
      
	 	 	 
	
                    Name

                    Function

                  	 
      	
                    Name

                    Function

                  

          

        

      

    

     

    
      
        
          
            
              	
                      NOVARTIS   initials:

                    	 
      	
                      ACCEPTOR   initials:

                    
	
                      This
      document contains proprietary information and may not be divulged without
      prior written approval of Contract Parties

                    
	 
      
	
                      QAA
      Novartis Genvec - Enclosure
      D       3/1

                    	
                       

                    	 
      	
                      Version1.0

                    

            

          

        

            

        * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

        

          
            
               

            

            
               

              
                

              

            

            
               

            

          

        

      

    

     

    QUALITY
AGREEMENT ON MANUFACTURING(, PACKAGING) AND TESTING 

      
        

      

    

     

    Annex
E : Health, Safety and Environmental Protection

    

    
      	
              1.

            	
              Novartis
      shall provide to GenVec a Material Safety Data Sheet for each Development
      Material which is proprietary to Novartis and which is provided to GenVec
      under this Agreement, recording all of the information which is known to
      Novartis at the time of preparing the Material Safety Data Sheet which may
      be relevant to health, safety and/or environmental
    protection.

            

    

    

    
      	
              2.

            	
              GenVec
      agrees to comply in all respects with the applicable laws and regulations
      on health, safety and environmental protection and with generally accepted
      standards of health, safety and environmental
  protection.

            

    

    

    
      	
              3.

            	
              The
      persons engaged in performing the Services shall have adequate training in
      health, safety and environmental protection issues associated with
      handling hazardous materials.

            

    

    

    
      	
              4.

            	
              GenVec
      warrants that all waste will be disposed of in compliance with all
      applicable laws and regulations, and that discarded printed material and
      products are not illegally used.

            

    

    

    
      	
              5.

            	
              GenVec
      shall use, handle and store all Basic Materials and Development Materials
      and any other materials used to perform the Services under suitable
      containment conditions.

            

    

    

    
      	
              6.

            	
              GenVec
      shall use, handle and store all Basic Materials and Development Materials
      and any other materials used to perform the Services with caution and
      prudence, since not all of the characteristics are necessarily known.
      Unless advised otherwise, GenVec shall proceed on the basis that the
      materials are hazardous.

            

    

    

    
      	
              7.

            	
              GenVec
      shall under no circumstances administer to any humans or animals any Basic
      Materials, Development Materials or any other materials used to perform
      the Services, except as otherwise agreed in writing in
      advance.

            

    

    

    
      	
              8.

            	
              GenVec
      shall return to Novartis or destroy, as requested by Novartis in writing,
      any Basic Materials, Development Materials or any other materials which
      remain unused upon completion of the performance of the Services. The
      GenVec shall ensure that any destruction of such materials is performed in
      accordance with all applicable laws and regulations and any written
      instructions of Novartis.

            

    

    

    
      	
              9.

            	
              GenVec
      shall inform Novartis without delay of any health, safety and/or
      environmental incident related to the Services or the Development
      Materials. Furthermore, GenVec shall inform Novartis without delay of any
      serious safety, health and/or environmental issues which are relevant to
      the performance of the Services or to the Development
      Materials.

            

    

        

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    QUALITY
AGREEMENT ON MANUFACTURING(, PACKAGING) AND TESTING 

      
        

      

    

     

    
      	
              10.

            	
              GenVec
      shall be fully liable with respect to any claim (whether from private
      parties or from public bodies), which may arise from GenVec’s failure to
      meet applicable occupational health, safety or environmental protection
      laws and/or regulations.

            

    

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    
       

       Agreement
for the Supply of Services Relating to

       Development
Materials 

        
          

        

      

    

     

    Annex
F

    

    WORK
ORDER for Project “* Manufacturing Development and Clinical Supply
Program”

    

    between

    

    
      
        
          
            	
                    GenVec,
      Inc.

                    65
      West Watkins Mill Road

                    Gaithersburg

                    Maryland
      20878

                    United
      States

                     

                  	
                    and

                  	
                    Novartis
      Pharma AG

                    Forum
      1

                    Novartis
      Campus

                    4056
      Basel

                    Switzerland

                  
	(hereinafter
      “GenVec”) 	 	
                    (hereinafter
      “Novartis”)

                  

          

        

      

    

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

     

    
      
         

      

      
        6

        
          

        

      

      
         

      

    

     

    
       Agreement
for the Supply of Services Relating to

       Development
Materials 

        
          

        

      

    

     

    
      
        
          	
                  Work
      Order No.: 1

                	
                  Novartis Project Code:
      CGF166

                
	
                  SUMMARY
      OF WORK AND COSTS:

                

        

      

       

      
        
          
            
              
                
                  
                    
                      
                        
                          
                            
                              
                                
                                  
                                    
                                      
                                        	 
      	 	
                                                Activity

                                              	 	 	
                                                Costs

                                                USD

                                              	 
	
                                                *

                                              	 	 	*	 	 	 	*	 
	
                                                *

                                              	 	 	*	 	 	 	*	 
	
                                                *

                                              	 	 	 *	 	 	 	*	 
	 	 	 	*	 	 	 	*	 
	 
      	 	
                                                *

                                              	 
	 	 	
                                                Total
      *USD

                                              	 

                                      

                                    

                                  

                                

                              

                            

                          

                        

                      

                    

                  

                

              

            

          

        

      

      
* The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    

     

    
      
         

      

      
        7

        
          

        

      

      
         

      

    

     

    
      Agreement
for the Supply of Services Relating to

      Development
Materials 

        
          

        

      

    

     

    
      	
              1.

            	
              LIST
      OF ATTACHMENTS:

            

    

     

    
      	
               
      

            	
              ·

            	
              Description
      of Work (Attachment A)

            

    

     

    
      	
               
      

            	
              ·

            	
              Invoicing
      Schedule (Attachment B)

            

    

     

    
      	
               
      

            	
              ·

            	
              Equipment
      (Attachment C)

            

    

     

    
      	
               
      

            	
              ·

            	
              Contact
      Persons and Addresses (Attachment
D)

            

    

     

    All of
these attachments shall form part of this Work Order. In the event of any
inconsistencies between this Work Order and any Attachments, this Work Order
shall prevail. In the event of any inconsistencies between the Attachments, the
order of precedence shall be the order in which the Attachments are listed
above.

    

    
      	
              2.

            	
              COST
      AND PAYMENT

            

    

    

    
      	
              Payment
      shall be made to GenVec according to Attachment B appended hereto and
      incorporated herein by reference. All costs outlined on Attachment B shall
      remain firm for the duration of the Services, unless otherwise agreed to
      in writing by the parties.

            

    

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
        8

        
          

        

      

      
         

      

    

    
       

      Agreement
for the Supply of Services Relating to

       Development
Materials 

        
          

        

      

    

     

    Attachment
A

    Description
of Work

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

     

    
      
         

      

      
        9

        
          

        

      

      
         

      

    

    Description
of Work: * and * Hath1 Manufacturing Development

    and
Clinical Supply Program

     

    GenVec is
pleased to provide a Description of Work and Estimate of Cost for
Manufacturing/Quality Programmatic Support of the * Lead and Back-up
Candidates.  This includes the following activities:
*

     

    This
Development Program covers a period of 6 years, starting in 2010 and concluding
in 2015 (due to 36 month stability program for cGMP materials).  Total
Estimated Cost for Projects #1-14 is$*.

     

    The
following is a break-down of the projected yearly costs for the 16
activities:

     

    *

     

    GenVec
CONFIDENTIAL

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    This cost
estimate is based upon the following detailed scope of work:

    

    
      	
               
      

            	
              1.

            	
              *

            

    

     

    The
goals and objectives of this project are:

    
      	
               
      

            	
              a.

            	
              *

            

    

     

    
      	
               
      

            	
              b.

            	
              *

            

    

     

    
      	
               
      

            	
              c.

            	
              *

            

    

     

    
      	
               
      

            	
              d.

            	
              *

            

    

     

    
      	
               
      

            	
              ·

            	
              *

            

    

     

    
      	
               
      

            	
              e.

            	
              *

            

    

     

    
      	
               
      

            	
              f.

            	
              *

            

    

     

    This
cost estimate does not include certain
studies may be required through the course of clinical development:

    
      	
               
      

            	
              a.

            	
              *

            

    

     

    
      	
               
      

            	
              b.

            	
              *

            

    

     

    
      	
               
      

            	
              c.

            	
              *

            

    

     

    Estimated Project Cost: $*

     

    GenVec
CONFIDENTIAL

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    *

     

    GenVec
CONFIDENTIAL

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    *

     

    GenVec
CONFIDENTIAL

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    *

     

    GenVec
CONFIDENTIAL

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    *

     

    GenVec
CONFIDENTIAL

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    *

     

    GenVec
CONFIDENTIAL

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    *

     

    GenVec
CONFIDENTIAL

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    
      
        
          	
                	
                  2.

                	
                  *

                

        

      

    

     

    The
goals and objectives of this project are:

    
      	
               
      

            	
              a.

            	
              *

            

    

     

    
      	
               
      

            	
              b.

            	
              *

            

    

     

    
      	
               
      

            	
              c.

            	
              *

            

    

     

    
      	
               
      

            	
              d.

            	
              *

            

    

     

    
      	
               
      

            	
              e.

            	
              *

            

    

     

    This
work does not
include certain options that were discussed at the Kick-Off
Meeting:

    
      	
               
      

            	
              d.

            	
              *

            

    

     

    
      	
               
      

            	
              e.

            	
              *

            

    

     

    
      	
               
      

            	
              f.

            	
              *

            

    

     

    Estimated
Project Cost:  $*

     

    
      
        	
              	
                2a. 

              	
                *

              

      

    

    Estimated
Project Cost:  $*

     

    
      
        	
              	
                2b. 

              	
                *

              

      

    

    Estimated
Project Cost:  $*

     

    GenVec
CONFIDENTIAL

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    *

     

    GenVec
CONFIDENTIAL

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    *

     

    GenVec
CONFIDENTIAL

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    *

     

    GenVec
CONFIDENTIAL

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    
      	
               
      

            	
              3.

            	
              *

            

    

     

    The
goals and objectives of this project are:

    
      	
               
      

            	
              a.

            	
              *

            

    

     

    
      	
               
      

            	
              b.

            	
              *

            

    

     

    
      	
               
      

            	
              c.

            	
              *

            

    

     

    
      	
               
      

            	
              d.

            	
              *

            

    

     

    
      	
               
      

            	
              e.

            	
              *

            

    

     

    
      	
               
      

            	
              f.

            	
              *

            

    

     

    
      	
               
      

            	
              g.

            	
              *

            

    

     

    
      	
               
      

            	
              h.

            	
              *

            

    

     

    
      	
               
      

            	
              i.

            	
              *

            

    

     

    
      	
               
      

            	
              j.

            	
              *

            

    

     

    
      	
               
      

            	
              k.

            	
              *

            

    

     

    
      	
               
      

            	
              l.

            	
              *

            

    

     

    
      	
               
      

            	
              m.

            	
              *

            

    

     

    
      	
               
      

            	
              n.

            	
              *

            

    

     

    
      	
               
      

            	
              o.

            	
              *

            

    

     

    
      	
               
      

            	
              p.

            	
              *

            

    

     

    
      	
               
      

            	
              q.

            	
              *

            

    

     

    Estimated
Project Cost:   $*

     

    GenVec
CONFIDENTIAL

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    *

     

    GenVec
CONFIDENTIAL

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    *

     

    GenVec
CONFIDENTIAL

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    
      	
              4.

            	
              *

            

    

     

    The
goals and objectives of this project are:

    
      	
               
      

            	
              a.

            	
              *

            

    

     

    
      	
               
      

            	
              b.

            	
              *

            

    

     

    
      	
               
      

            	
              c.

            	
              *

            

    

     

    
      	
               
      

            	
              d.

            	
              *

            

    

     

    
      	
               
      

            	
              e.

            	
              *

            

    

     

    
      	
               
      

            	
              f.

            	
              *

            

    

     

    
      	
               
      

            	
              g.

            	
              *

            

    

     

    
      	
               
      

            	
              h.

            	
              *

            

    

     

    
      	
               
      

            	
              i.

            	
              *

            

    

     

    
      	
               
      

            	
              j.

            	
              *

            

    

     

    Estimated
Project Cost:   $*

     

    GenVec
CONFIDENTIAL

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    *

     

    GenVec
CONFIDENTIAL

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    *

     

    GenVec
CONFIDENTIAL

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    
      	
               
      

            	
              5.

            	
              *

            

    

     

    The
goals and objectives of this project are:

    
      	
               
      

            	
              a.

            	
              *

            

    

     

    
      	
               
      

            	
              b.

            	
              *

            

    

     

    
      	
               
      

            	
              c.

            	
              *

            

    

     

    
      	
               
      

            	
              d.

            	
              *

            

    

     

    
      	
               
      

            	
              e.

            	
              *

            

    

     

    
      	
               
      

            	
              f.

            	
              *

            

    

     

    
      	
               
      

            	
              g.

            	
              *

            

    

     

    
      	
               
      

            	
              h.

            	
              *

            

    

     

    
      	
               
      

            	
              i.

            	
              *

            

    

     

    Estimated
Project Cost:   $*

     

    GenVec
CONFIDENTIAL

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    *

     

    GenVec
CONFIDENTIAL

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    *

     

    GenVec
CONFIDENTIAL

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    
      	
            	
              6.

            	
              *

            

    

     

    The
goals and objectives of this project are:

    
      	
               
      

            	
              a.

            	
              *

            

    

     

    
      	
               
      

            	
              b.

            	
              *

            

    

     

    
      	
               
      

            	
              c.

            	
              *

            

    

     

    
      	
               
      

            	
              d.

            	
              *

            

    

     

    Estimated
Project Cost:   $*

     

    GenVec
CONFIDENTIAL

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    *

     

    GenVec
CONFIDENTIAL

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    *

     

    GenVec
CONFIDENTIAL

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    *

     

    GenVec
CONFIDENTIAL

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    *

     

    GenVec
CONFIDENTIAL

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    
      	
               
      

            	
              7.

            	
              *

            

    

     

    The goals and objectives of this
project are:

    
      	
               
      

            	
              a.

            	
              *

            

    

     

    
      	
               
      

            	
              b.

            	
              *

            

    

     

    
      	
               
      

            	
              c.

            	
              *

            

    

     

    
      	
               
      

            	
              d.

            	
              *

            

    

     

    
      	
               
      

            	
              e.

            	
              *

            

    

     

    
      	
               
      

            	
              f.

            	
              *

            

    

     

    This
work does not
include the following:

    
      	
               
      

            	
              a.

            	
              *

            

    

     

    
      	
               
      

            	
              b.

            	
              *

            

    

     

    
      	
               
      

            	
              c.

            	
              *

            

    

     

    
      	
               
      

            	
              d.

            	
              *

            

    

     

    Estimated
Project Cost:   $*

     

    GenVec
CONFIDENTIAL

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    *

     

    GenVec
CONFIDENTIAL

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    *

     

    GenVec
CONFIDENTIAL

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    *

     

    GenVec
CONFIDENTIAL

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    *

     

    GenVec
CONFIDENTIAL

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    
      	
              
              

            	
              8.

            	
              *

            

    

     

    The
goals and objectives of this project are:

    
      	
               
      

            	
              a.

            	
              *

            

    

     

    
      	
               
      

            	
              b.

            	
              *

            

    

     

    
      	
               
      

            	
              c.

            	
              *

            

    

     

    
      	
               
      

            	
              d.

            	
              *

            

    

     

    
      	
               
      

            	
              e.

            	
              *

            

    

     

    
      	
               
      

            	
              f.

            	
              *

            

    

     

    
      	
               
      

            	
              g.

            	
              *

            

    

     

    Estimated
Project Cost:      $*

     

    GenVec
CONFIDENTIAL

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    *

     

    GenVec
CONFIDENTIAL

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    *

     

    GenVec
CONFIDENTIAL

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    

    
      	
            	
              9.

            	
              *

            

    

     

    The
goals and objectives of this project are:

    
      	
               
      

            	
              a.

            	
              *

            

    

     

    
      	
               
      

            	
              b.

            	
              *

            

    

     

    
      	
               
      

            	
              c.

            	
              *

            

    

     

    
      	
               
      

            	
              d.

            	
              *

            

    

     

    
      	
               
      

            	
              e.

            	
              *

            

    

     

    
      	
               
      

            	
              f.

            	
              *

            

    

     

    
      	
               
      

            	
              g.

            	
              *

            

    

     

    
      	
               
      

            	
              h.

            	
              *

            

    

     

    
      	
               
      

            	
              i.

            	
              *

            

    

     

    
      	
               
      

            	
              j.

            	
              *

            

    

     

    
      	
               
      

            	
              k.

            	
              *

            

    

     

    
      	
               
      

            	
              l.

            	
              *

            

    

     

    
      	
               
      

            	
              m.

            	
              *

            

    

     

    
      	
               
      

            	
              n.

            	
              *

            

    

     

    
      	
               
      

            	
              o.

            	
              *

            

    

     

    
      	
               
      

            	
              p.

            	
              *

            

    

     

    
      	
               
      

            	
              q.

            	
              *

            

    

     

    Estimated
Project Cost:     $*

     

    GenVec
CONFIDENTIAL

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    *

     

    GenVec
CONFIDENTIAL

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    *

     

    GenVec
CONFIDENTIAL

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    

    
      	
            	
              10.

            	
              *

            

    

     

    The
goals and objectives of this project are:

    
      	
               
      

            	
              a.

            	
              *

            

    

     

    
      	
               
      

            	
              b.

            	
              *

            

    

     

    
      	
               
      

            	
              c.

            	
              *

            

    

     

    
      	
               
      

            	
              d.

            	
              *

            

    

     

    
      	
               
      

            	
              e.

            	
              *

            

    

     

    
      	
               
      

            	
              f.

            	
              *

            

    

     

    
      	
               
      

            	
              g.

            	
              *

            

    

     

    
      	
               
      

            	
              h.

            	
              *

            

    

     

    
      	
               
      

            	
              i.

            	
              *

            

    

     

    
      	
               
      

            	
              j.

            	
              *

            

    

     

    Estimated
Project Cost:      $*

     

    GenVec
CONFIDENTIAL

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    *

     

    GenVec
CONFIDENTIAL

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    

    
      	
            	
              11.

            	
              *

            

    

     

    The
goals and objectives of this project are:

    
      	
               
      

            	
              a.

            	
              *

            

    

     

    
      	
               
      

            	
              b.

            	
              *

            

    

     

    
      	
               
      

            	
              c.

            	
              *

            

    

     

    
      	
               
      

            	
              d.

            	
              *

            

    

     

    
      	
               
      

            	
              e.

            	
              *

            

    

     

    
      	
               
      

            	
              f.

            	
              *

            

    

     

    
      	
               
      

            	
              g.

            	
              *

            

    

     

    
      	
               
      

            	
              h.

            	
              *

            

    

     

    
      	
               
      

            	
              i.

            	
              *

            

    

     

    Estimated
Project Cost:        $*

     

    GenVec
CONFIDENTIAL

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    *

     

    GenVec
CONFIDENTIAL

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    *

     

    GenVec
CONFIDENTIAL

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    

    
      	
            	
              12.

            	
              *

            

    

     

    The
goals and objectives of this project are:

    
      	
               
      

            	
              a.

            	
              *

            

    

     

    
      	
               
      

            	
              b.

            	
              *

            

    

     

    
      	
               
      

            	
              c.

            	
              *

            

    

     

    
      	
               
      

            	
              d.

            	
              *

            

    

     

    Estimated
Project Cost:      $*

     

    GenVec
CONFIDENTIAL

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    *

     

    GenVec
CONFIDENTIAL

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    *

     

    GenVec
CONFIDENTIAL

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    *

     

    GenVec
CONFIDENTIAL

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    *

     

    GenVec
CONFIDENTIAL

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    
      	 	
              13.

            	
              *

            

    

     

    The goals and objectives of this
project are:

    
      	
               
      

            	
              a.

            	
              *

            

    

     

    
      	
               
      

            	
              b.

            	
              *

            

    

     

    
      	
               
      

            	
              c.

            	
              *

            

    

     

    
      	
               
      

            	
              d.

            	
              *

            

    

     

    
      	
               
      

            	
              e.

            	
              *

            

    

     

    
      	
               
      

            	
              f.

            	
              *

            

    

     

    Estimated
Project
Cost:         $*

     

    GenVec
CONFIDENTIAL

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    *

     

    GenVec
CONFIDENTIAL

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    

    
      	
            	
              14.

            	
              *

            

    

     

    The
goals and objectives of this project are:

    
      	
               
      

            	
              a.

            	
              *

            

    

     

    
      	
               
      

            	
              b.

            	
              *

            

    

     

    
      	
               
      

            	
              c.

            	
              *

            

    

     

    
      	
               
      

            	
              i.

            	
              *

            

    

     

    
      	
               
      

            	
              ii.

            	
              *

            

    

     

    
      	
               
      

            	
              d.

            	
              *

            

    

     

    
      	
               
      

            	
              i.

            	
              *

            

    

     

    
      	
               
      

            	
              ii.

            	
              *

            

    

     

    
      	
               
      

            	
              e.

            	
              *

            

    

     

    
      	
               
      

            	
              f.

            	
              *

            

    

     

    
      	
               
      

            	
              g.

            	
              *

            

    

     

    
      	
               
      

            	
              h.

            	
              *

            

    

     

    
      	
               
      

            	
              i.

            	
              *

            

    

     

    
      	
               
      

            	
              ii.

            	
              *

            

    

     

    
      	
               
      

            	
              iii.

            	
              *

            

    

     

    *

     

    Estimated
Project Cost:     $*

     

    GenVec
CONFIDENTIAL

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    *

     

    GenVec
CONFIDENTIAL

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    *

     

    GenVec
CONFIDENTIAL

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    Details
on estimated cost by quarter for each year are provided on the following
pages:

     

    GenVec
CONFIDENTIAL

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    *

     

    GenVec
CONFIDENTIAL

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    *

     

    GenVec
CONFIDENTIAL

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    *

     

    GenVec
CONFIDENTIAL

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    *

     

    GenVec
CONFIDENTIAL

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    *

     

    GenVec
CONFIDENTIAL

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    *

     

    GenVec
CONFIDENTIAL

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    

    Attachment
B

    Invoicing
Schedule

    

    GenVec
shall send invoices according Section3 of Annex B of the Agreement.

    

    If not
otherwise indicated in the table below, invoices shall be sent as
follows:

    

    (i) for
the * invoices shall be
sent by *
and

    

    (ii) for
the *.

    

    Schedule
for 2010:

     

    
      
        
          
            
              
                
                  
                    
                      
                        	 
      	 
      	
                                Q1

                              	 
      	 
      	
                                Q2

                              	 
      	
                                Q3

                              	 
      	
                                Q4

                              	 
      	
                                Total

                              
	
                                Cost
      USD

                              	 
      	
                                *

                              	 
      	 
      	
                                *

                              	 
      	
                                *

                              	 
      	
                                *

                              	 
      	
                                *

                              
	
                                Invoice

                              	 
      	
                                *

                              	 
      	
                                *

                              	 
      	
                                *

                              	 
      	 
      
	
                                Comments

                              	 
      	
                                *

                              	 
      	 
      	 
      	 
      	 
      	 
      	 
      	 
      	 
      

                      

                    

                  

                

              

            

          

        

      

    

     

    For more
details on quaterly costs per activity and schedule for the following years, see
Attachement A (Description of Work).

     

    Invoices should be sent to
:

    

    
      
        
          
            	
                    Novartis
      Pharma AG

                    Zentraler
      Faktureneingang

                    Attention:
      Petra Meissner*

                    Postfach

                    CH-4002
      Basel

                    Switzerland

                     

                    * or
      such other person as may be designated by Novartis from time to
      time

                  

          

        

      

    

     

    GenVec
CONFIDENTIAL

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    Attachment
C

     

    Equipment

     

    Genvec
shall purchase the Equipment as described in Attachement A:

    

    
      
        
          
            
              
                
                  
                    
                      
                        	
                                Activity

                              	 
      	
                                Equipment

                              	 
      	
                                Cost

                                USD

                              
	
                                *

                              	 
      	
                                *

                              	 
      	
                                *

                              
	
                                *

                              	 
      	
                                *

                              	 
      	
                                *

                              
	
                                *

                              	 
      	
                                *

                              	 
      	
                                *

                              
	
                                *

                              	 
      	
                                *

                              	 
      	
                                *

                              
	
                                SUM

                              	 
      	 
      	 
      	
                                *

                              

                      

                    

                  

                

              

            

          

        

      

    

     

    Costs for
the Equipment is included in the invoicing schedule in Attachement B and shall
be defined on an invoice as such.

     

    GenVec
CONFIDENTIAL

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    Attachment
D

    

    Contact persons and
addresses:

    

    Novartis
Pharma AG

    Petra
Meissner

    Technical
Project Leader

    Postfach

    4002
Basel

    Switzerland

    Phone:
+41 61 32 46766

    Fax: +41
61 3247180

    Email:
petra.meissner@novartis.com

     

    Genvec,
Inc.

    Bryan T.
Butman

    Senior
Vice President, Vector Operations

    65 West
Watkins Mill Road

    Gaithersburg

    Maryland
20878

    United
States

    Phone: +1
240-632-5554

    Fax: +1
301 9441896

    Email:
bbutman@genvec.com

    

    Shipment to Novartis
:

    

    Novartis
Pharmaceuticals Corporation

    Drug
Supply Management

    One
Health Plaza

    East
Hanover, NJ 07936-1080

    USA

     

    GenVec
CONFIDENTIAL

     

    * The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00176-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00176-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00176-of-00352.parquet"}]]